Document:

Exhibit 10.1

 Exhibit 10.1 

SETTLEMENT AGREEMENT 

This Settlement Agreement (“Agreement”) is entered into among the United States of America, acting through the United States
Department of Justice and the United States Attorney’s Office for the Northern District of Georgia and on behalf of the Office of Inspector General of the Department of Health and Human Services (“OIG-HHS”), the TRICARE Management
Activity (“TMA”), the United States Office of Personnel Management (“OPM”), the United States Department of Veterans Affairs (“VA”), and Office of Workers’ Compensation Programs of the United States Department of
Labor (“DOL-OWCP”) (collectively “the United States”); Dr. Amy M. Lang, Charles J. Rushin, Cher Beilfuss, Kathleen O’Connor-Masse, and Albert Edward Hallivis (collectively, “Relators”); Allergan, Inc. and
Allergan USA, Inc. (referred to individually and collectively as “Allergan”), through their authorized representatives. Collectively, all of the above will be referred to as “the Parties.” 

PREAMBLE 

As a preamble to this Agreement, the Parties agree to the following: 

A.         Allergan, Inc. and Allergan USA, Inc. are Delaware corporations headquartered in
Irvine, California. At all relevant times herein, Allergan developed, manufactured, distributed, marketed, and sold pharmaceutical products in the United States, including a drug sold under the trade name of
Botox® Therapeutic
(“Botox®”), which is billed to federal health care programs under HCPCS code J0585. 

B.         Relators have filed the following qui tam actions against Allergan
captioned as follows (collectively the “Civil Actions”): 
  

	 	(i)	United States ex rel. Amy M. Lang and Charles J. Rushin v. Allergan, Inc., Civ. No. 1:07-cv-1288-WSD (N.D. Ga.) (hereinafter “Civil Action I”);

	 	(ii)	United States ex rel. Cher Beilfuss and Kathleen O’Connor-Masse v. Allergan, Inc., Civ. No. 1:08-cv-1883-WSD (N.D. Ga.) (hereinafter “Civil Action
II”); and 

  

	 	(iii)	United States ex rel. Albert Edward Hallivis v. Allergan, Inc. a/k/a Allergan USA, Inc., Civ. No. 1:09-cv-3434-WSD (N.D. Ga.) (hereinafter “Civil
Action III”). 

 The United States intervened in Civil Action I and Civil Action II on April 2, 2010. 

C.         On such date as may be determined by the Court, Allergan, Inc. will enter into a
plea of guilty pursuant to Fed. R. Crim. P. 11(c)(1)(C) (the “Plea Agreement”) to an information to be filed in United States v. Allergan, Inc., Criminal Action No. [to be assigned] (Northern District of Georgia) (the “Criminal
Action”) that will allege a violation of Title 21, United States Code, Sections 331(a) and 333(a)(1), a misdemeanor, namely, the introduction into interstate commerce of a misbranded drug,
Botox® , in violation of the Food, Drug and Cosmetic Act. 

D.         Allergan has filed a declaratory judgment action pending in the United States
District Court for the District of Columbia, captioned Allergan, Inc. v. United States, et al., 1:09-cv-01879 (D.D.C.) (hereinafter, the “D.C. Litigation”). The D.C. Litigation is currently stayed at the joint request of Allergan
and the United States. 
 E.         Allergan has entered or will be entering into
separate settlement agreements, described in Paragraph 1.b., below (hereinafter referred to as the “Medicaid State Settlement Agreements”) with certain states and the District of Columbia in settlement of the Covered Conduct. States with
which Allergan executes a Medicaid State Settlement Agreement in the form to which Allergan and the National Association of Medicaid Fraud Control Units (“NAMFCU”) Negotiating Team have agreed, or in a form otherwise agreed to by Allergan
and an individual State, shall be defined as “Medicaid Participating States.” 
  

 -2- 

 F.         The United States alleges that
Allergan caused claims for payment for Botox® to be submitted to the Medicare Program (“Medicare”),
Title XVIII of the Social Security Act, 42 U.S.C. §§ 1395-1395hhh. The United States further alleges that Allergan caused claims for payment for
Botox® to be submitted to the Medicaid Program (“Medicaid”), Title XIX of the Social Security Act, 42
U.S.C. §§ 1396-1396v. The United States further alleges that Allergan caused claims for payment of Botox®
 to be submitted to the TRICARE program, 10 U.S.C. §§ 1071-1109; the Federal Employees Health Benefits Program (“FEHBP”), 5 U.S.C. §§ 8901-8914; the following DOL-OWCP programs: the Federal Employees’
Compensation Act (“FECA”), 5 U.S.C. § 8101 et seq.; the Energy Employees Occupational Illness Compensation Program Act (“EEOICPA”), 42 U.S.C. § 7384 et seq.; and the Black Lung Benefits Act
(“BLBA”), 30 U.S.C. § 901 et seq.; and caused purchases of Botox® by the VA, 38
U.S.C. §§ 1701-1743 (collectively, the “Other Federal Health Care Programs”). 

G.         The United States contends that it and the Medicaid Participating States have
certain civil claims, as specified in Paragraph 2, below, against Allergan for engaging in the following conduct during the period January 1, 2001 through December 31, 2008 (hereinafter referred to as the “Covered Conduct”):

  

	 	(i)	Allergan promoted the sale and use of
Botox® for uses that were not approved by the Food and Drug Administration as safe and effective (including but
not limited to headache, pain, spasticity, and overactive bladder) (“unapproved uses”) and promoting the drug for unapproved uses renders the drug misbranded in violation of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 331,
et seq. Some of these unapproved uses were not medically accepted indications for which the United States and state Medicaid programs provided coverage for
Botox®; 

  

	 	(ii)	Allergan made and/or disseminated unsubstantiated and/or misleading representations or statements that
Botox® was safe and effective for some of these unapproved uses; 

 

 -3- 

	 	(iii)	Allergan instructed health care professionals to miscode claims for the treatment of headache and pain using inapplicable diagnosis codes (including but not limited to
codes for spasm of muscle (ICD-9-CM 728.5), other facial nerve disorders (ICD-9-CM 351.8), spasmodic torticollis (ICD-9-CM 333.83), and torticollis unspecified (ICD-9-CM 723.5)) to ensure payment by Medicare, Medicaid and the Other Federal Health
Care Programs; and 

  

	 	(iv)	Allergan offered and paid illegal remuneration to health care professionals that was intended to induce them to promote and/or prescribe
Botox®. 

As a result of the foregoing conduct, the Government alleges that Allergan caused false or fraudulent claims for
Botox® to be submitted to, or caused purchases by, Medicare, Medicaid and the Other Federal Health Care
Programs. 
 With respect only to claims for
Botox® submitted to Medicaid, Medicare and the Other Federal Health Care Programs with diagnosis codes for
overactive bladder and neurogenic bladder conditions (ICD-9-CM 788.30, 788.31, 788.32, 788.33, 788.34, and 599.82), the Covered Conduct extends from January 1, 2001 through December 31, 2009. 

Notwithstanding Preamble Paragraph G(iii), the Covered Conduct does not include conduct relating to claims for
Botox® submitted to Medicaid, Medicare and the Other Federal Health Care Programs with the diagnosis codes
ICD-9-CM 333.81 (blepharospasm) and ICD-9- CM 705.21, 705.22, and 780.8 (hyperhidrosis). 

H.         The United States also contends that it has certain administrative claims against
Allergan, as set forth in Paragraphs 4 through 7, below, for engaging in the Covered Conduct. 

I.         This Agreement is made in compromise of disputed claims. This Agreement is not an
admission of facts or liability by Allergan. With the exception of such admissions that are made in connection with any guilty plea by Allergan in connection with the Criminal Action, Allergan expressly denies the allegations of the United States
and the Relators as set forth herein 
  

 -4- 

 
and in the Civil Actions and denies that it engaged in any wrongful conduct in connection with the Covered Conduct. This Agreement is not a concession by the United States that its claims are not
well founded. Neither this Agreement, its execution, nor the performance of any obligation under it, including any payment, nor the fact of any settlement, is intended to be, or shall be understood as, an admission of liability or wrongdoing, or
other expression reflecting on the merits of the dispute by Allergan. 
 J.        To
avoid the delay, uncertainty, inconvenience, and expense of protracted litigation of the above claims, the Parties reach a full and final settlement pursuant to the Terms and Conditions below. 

 

 -5- 

 TERMS AND CONDITIONS 

NOW, THEREFORE, in reliance on the representations contained herein and in consideration of the mutual promises, covenants, and
obligations in this Agreement, and for good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows: 

1.        Allergan agrees to pay to the United States and the Medicaid Participating States,
collectively, the sum of Two Hundred and Twenty Five Million Dollars ($225,000,000), plus accrued interest at the rate of 3.5% per annum from January 25, 2010, and continuing until and including the day of payment (the “Settlement
Amount”). The Settlement Amount shall constitute a debt immediately due and owing to the United States and the Medicaid Participating States on the Effective Date of this Agreement. This debt shall be discharged by payments to the United States
and the Medicaid Participating States, under the following terms and conditions: 

(a)        Allergan shall pay to the United States the sum of $210,150,000 plus accrued interest
as set forth above (“Federal Settlement Amount”). The Federal Settlement Amount shall be paid by electronic funds transfer pursuant to written instructions from the United States no later than seven (7) business days after
(i) this Agreement is fully executed by the Parties and delivered to Allergan’s attorneys; or (ii) the Court accepts a Fed. R. Crim. P. 11(c)(1)(C) guilty plea as described in Preamble Paragraph C in connection with the Criminal
Action and imposes the agreed upon sentence, whichever occurs later. 

(b)        Allergan shall deposit the sum of $14,850,000, plus accrued interest as set forth
above (“Medicaid State Settlement Amount”) into one or more interest-bearing money market or bank accounts (the “State Settlement Accounts”) that are held in the name of Allergan but segregated from other Allergan accounts, and
shall pay the Medicaid Participating States 
  

 -6- 

 
from the State Settlement Accounts pursuant to written instructions from the NAMFCU Negotiating Team and under the terms and conditions of the Medicaid State Settlement Agreements that Allergan
will enter into with the Medicaid Participating States. 
 (c)        Contingent upon
the United States receiving the Federal Settlement Amount from Allergan, the United States agrees to pay, as soon as feasible upon receipt, Amy M. Lang and Charles J. Rushin $37,827,000, plus a proportionate share of the actual accrued interest paid
to the United States by Allergan, as set forth in Paragraph 1.a., above, (“Relators’ Share”) as Relators’ share of the proceeds pursuant to 31 U.S.C. § 3730(d). No other relator payments shall be made by the United States
with respect to the matters covered by this Agreement. All Relators represent that they will abide by the terms of any written and executed separate agreements that they may have entered into with one or more of the other Relators concerning the
allocation of the Relators’ Share among themselves. 
 (d)        If
Allergan’s agreed-upon guilty plea pursuant to Fed. R. Crim. P. 11(c)(1)(C) in the Criminal Action described in Preamble Paragraph C is not accepted by the Court or the Court does not impose the agreed-upon sentence for whatever reason, this
Agreement shall be null and void at the option of either the United States or Allergan. If either the United States or Allergan exercises this option, which option shall be exercised by notifying all Parties, through counsel, in writing within five
(5) business days of the Court’s decision, the Parties will not object and this Agreement will be rescinded. If this Agreement is rescinded, Allergan will not plead, argue or otherwise raise any defenses under the theories of statute of
limitations, laches, estoppel or similar theories, to any civil or administrative claims, actions or proceedings arising from the Covered Conduct that are brought by the United States within 90

  

 -7- 

 
calendar days of rescission, except to the extent such defenses were available on the day on which the qui tam complaints listed in Preamble Paragraph B, above, were filed.

 (e)        If the stay of the D.C. Litigation described in Preamble Paragraph D is
lifted before Allergan dismisses with prejudice the D.C. Litigation pursuant to Paragraph 19, below, this Agreement shall be null and void at the option of either the United States or Allergan. If either the United States or Allergan exercises this
option, which option shall be exercised by notifying all Parties, through counsel, in writing within five (5) business days of the Court’s decision to lift the stay, the Parties will not object and this Agreement will be rescinded. If this
Agreement is rescinded, Allergan will not plead, argue or otherwise raise any defenses under the theories of statute of limitations, laches, estoppel or similar theories, to any civil or administrative claims, actions or proceedings arising from the
Covered Conduct that are brought by the United States within 90 calendar days of rescission, except to the extent such defenses were available on the day on which the qui tam complaints listed in Preamble Paragraph B, above, were
filed. 
 2.        Subject to the exceptions in Paragraph 8 (concerning excluded
claims), below, in consideration of the obligations of Allergan set forth in this Agreement, and conditioned upon Allergan’s full payment of the Settlement Amount, the United States (on behalf of itself, its officers, agents, agencies, and
departments) agrees to release Allergan, its predecessors, and its current and former divisions, parents, affiliates, subsidiaries, successors and assigns, and their current and former directors, officers, and employees from any civil or
administrative monetary claim the United States has or may have for the Covered Conduct under the False Claims Act, 31 U.S.C. §§ 3729-3733; the Civil Monetary Penalties Law, 42 U.S.C. § 1320a-7a; the Program Fraud Civil Remedies Act,
31 U.S.C. §§ 3801-3812; any statutory provision for which the Civil 
  

 -8- 

 
Division of the Department of Justice has actual and present authority to assert and compromise pursuant to 28 C.F.R. Part 0, Subpart I, Section 0.45(d); or the common law theories of payment by
mistake, fraud, disgorgement, unjust enrichment, and, if applicable, breach of contract. 

3.        Subject to the exceptions in Paragraph 8 (concerning excluded claims), below, in
consideration of the obligations of Allergan in this Agreement, conditioned upon Allergan’s full payment of the Settlement Amount, Relators, for themselves and for their heirs, successors, attorneys, agents, and assigns, agree to release
Allergan, its predecessors, and its current and former divisions, parents, affiliates, subsidiaries, successors and assigns, and their current and former directors, officers, and employees from any liability to Relators arising from any claim the
United States has, may have, or could have asserted relating to the Covered Conduct, and from all liability, claims, demands, actions or causes of action whatsoever existing as of the Effective Date of this Agreement, whether known or unknown, fixed
or contingent, in law or in equity, in contract or in tort, under any federal or state statute or regulation or that they or their heirs, successors, attorneys, agents and assigns otherwise would have standing to bring, including any liability
arising from the filing of the Civil Actions, except for: (1) claims for attorneys’ fees, expenses and costs pursuant to 31 U.S.C. § 3730(d); (2) claims for a Relator’s Share under the Medicaid State Settlement Agreements;
and (3) any employment discrimination claims Albert Edward Hallivis may have against Allergan. 

4.        In consideration of the obligations of Allergan in this Agreement and the Corporate
Integrity Agreement (CIA) entered into between OIG-HHS and Allergan, Inc., and conditioned upon Allergan’s full payment of the Settlement Amount, OIG-HHS agrees to release and refrain from instituting, directing, or maintaining any
administrative action seeking exclusion from Medicare, Medicaid, and other Federal health care programs (as defined in 42 U.S.C. § 

 

 -9- 

 
1320a-7b(f)) against Allergan under 42 U.S.C. § 1320a-7a (Civil Monetary Penalties Law), or 42 U.S.C. § 1320a-7(b)(7) (permissive exclusion for fraud, kickbacks, and other prohibited
activities) for the Covered Conduct, or against Allergan, Inc. under 42 U.S.C. § 1320a-7(b)(1) based on Allergan, Inc.’s agreement to plead guilty to the charge in the Allergan Criminal Action referenced above in Preamble Paragraph C,
except as reserved in Paragraph 8 (concerning excluded claims), below, and as reserved in this Paragraph. The OIG-HHS expressly reserves all rights to comply with any statutory obligations to exclude Allergan from Medicare, Medicaid, and other
Federal health care programs under 42 U.S.C. § 1320a-7(a) (mandatory exclusion) based upon the Covered Conduct. Nothing in this Paragraph precludes the OIG-HHS from taking action against entities or persons, or for conduct and practices, for
which claims have been reserved in Paragraph 8, below. 
 5.        In consideration of
the obligations of Allergan in this Agreement, and conditioned upon Allergan’s full payment of the Settlement Amount, TMA agrees to release and refrain from instituting, directing, or maintaining any administrative action seeking exclusion or
suspension from the TRICARE Program against Allergan, its predecessors, and its current and former divisions, parents, affiliates, subsidiaries, successors and assigns, and their current and former directors, officers, and employees under 32 C.F.R.
§ 199.9 for the Covered Conduct, except as reserved in Paragraph 8 (concerning excluded claims), below, and as reserved in this Paragraph. TMA expressly reserves authority to exclude Allergan from the TRICARE Program under 32 C.F.R.
§§ 199.9 (f)(1)(i)(A), (f)(1)(i)(B), and (f)(1)(iii), based upon the Covered Conduct. Nothing in this Paragraph precludes TMA or the TRICARE Program from taking action against entities or persons, or for conduct and practices, for which
claims have been reserved in Paragraph 8, below. 
  

 -10- 

 6.        In consideration of the obligations of
Allergan in this Agreement, and conditioned upon Allergan’s full payment of the Settlement Amount, OPM agrees to release and refrain from instituting, directing, or maintaining any administrative action against Allergan, its predecessors, and
its current and former divisions, parents, affiliates, subsidiaries, successors and assigns, and their current and former directors, officers, and employees under 5 U.S.C. § 8902a or 5 C.F.R. Part 919 for the Covered Conduct, except as reserved
in Paragraph 8 (concerning excluded claims), below, and except if excluded by the OIG-HHS pursuant to 42 U.S.C. § 1320a-7(a). Nothing in this Paragraph precludes OPM from taking action against entities or persons, or for conduct and practices,
for which claims have been reserved in Paragraph 8, below. 
 7.        In consideration
of the obligations of Allergan in this Agreement, and conditioned upon Allergan’s full payment of the Settlement Amount, DOL-OWCP agrees to release and refrain from instituting, directing, or maintaining any administrative action seeking
exclusion and debarment from the FECA, EEOICPA and BLBA programs against Allergan, its predecessors, and its current and former divisions, parents, affiliates, subsidiaries, successors and assigns, and their current and former directors, officers,
and employees under 20 C.F.R. §§ 10.815, 30.715 and 702.431 for the Covered Conduct, except as reserved in Paragraph 8 (concerning excluded claims), below and except if excluded by the OIG-HHS pursuant to 42 U.S.C. § 1320a-7(a).
Nothing in this Paragraph precludes the OWCP of the DOL from taking action against entities or persons, or for conduct and practices, for which claims have been reserved in Paragraph 8, below. 

8.        Notwithstanding any term of this Agreement, the following claims of the United States
are specifically reserved and excluded from the scope and terms of the Agreement as to any entity or person (including Allergan and the Relators): 
  

 -11- 

 (a)        Any civil, criminal, or administrative
liability arising under Title 26, U.S. Code (Internal Revenue Code); 
 (b)        Any
criminal liability; 
 (c)        Except as explicitly stated in this Agreement, any
administrative liability, including mandatory exclusion from Federal health care programs; 

(d)        Any liability to the United States (or its agencies) for any conduct other than the
Covered Conduct; 
 (e)        Any liability based upon such obligations as are created
by this Agreement; 
 (f)        Any liability for express or implied warranty claims
or other claims for defective or deficient products or services, including quality of goods and services; 

(g)        Any liability for personal injury or property damage or for other consequential
damages arising from the Covered Conduct; 
 (h)        Any liability for failure to
deliver goods or services due; and 
 (i)        Any liability of individuals
(including current or former directors, officers, employees, or agents of Allergan) who receive written notification that they are the target of a criminal investigation, are criminally indicted or charged, or are convicted, or who enter into a
criminal plea agreement. 
 9.      Relators and their heirs, successors, attorneys, agents, and
assigns agree not to object to this Agreement and agree and confirm that this Agreement is fair, adequate, and reasonable under all the circumstances, pursuant to 31 U.S.C. § 3730(c)(2)(B), and expressly waive the opportunity for a hearing on
any objection to this Agreement pursuant to 31 U.S.C. § 3730(c)(2)(B). Conditioned upon the United States’ payment of the Relators’ Share, as 

 

 -12- 

 
set forth in Paragraph 1.c., above, Relators for themselves individually, and for their heirs, successors, agents, and assigns, fully and finally release, waive, and forever discharge the United
States, and its officers, agents, and employees, from any claims arising from or relating to 31 U.S.C. § 3730; from any claims arising from the filing of the Civil Actions; and from any other claims for a share of the Settlement Amount or
payment of any sort from the United States relating to the Agreement or the filing of the Civil Actions; and in full settlement of any claims Relators may have under this Agreement. This Agreement does not resolve or in any manner affect any claims
the United States has or may have against the Relators arising under Title 26, U.S. Code (Internal Revenue Code), or any claims arising under this Agreement. 

10.    Conditioned upon the United States’ payment of the Relators’ Share, as set forth in Paragraph 1.c.,
above, the Relators, for themselves, and for their respective heirs, successors, attorneys, agents, and assigns: 

(a)        hereby fully and finally release and forever discharge Allergan, its predecessors,
and its current and former divisions, parents, affiliates, subsidiaries, successors, and assigns, and their current and former officers, directors, trustees, agents, servants, employees, representatives, attorneys, consultants, executors, and
administrators (collectively, “Allergan Releasees”) from any and all claims for relief, actions, rights, causes of action, suits, debts, obligations, liabilities, demands, losses, damages (including treble damages and any civil penalties),
punitive damages, costs, and expenses of any kind, character, or nature whatsoever, known or unknown, fixed or contingent, in law or in equity, in contract or in tort, or under any federal or state statute or regulation or otherwise that Relators or
their heirs, successors, attorneys, agents or assigns would have standing to bring, and which Relators or their heirs, successors, attorneys, agents, or assigns may now have or claim to have against the Allergan

  

 -13- 

 
Releasees, arising in any way out of or connected in any way with the facts, claims, and circumstances alleged in, arising under, or arising from the filing of the Civil Actions, or from any
other past activities and actions of the Allergan Releasees, except for: (1) claims for attorneys’ fees, expenses and costs pursuant to 31 U.S.C. § 3730(d); (2) claims for a Relators’ Share under the Medicaid State
Settlement Agreements; and (3) any employment discrimination claims that Albert Edward Hallivis may have against Allergan; and 

(b)        agree not to disseminate any documents or communications in their possession or
control, or information from such documents or communications, that can be readily identified as having been created in whole or in part by, or at the direction of, Allergan. In this regard, Relators and their counsel will make a good faith effort
to identify all such materials. The obligations in this subparagraph do not apply: (1) to documents or information in the public record or domain; (2) to the extent that compliance with the obligation would conflict with a statute or
regulation; (3) if disclosure is required by a subpoena or court order; or (4) in the case of employee Albert Edward Hallivis, to the degree he is authorized by Allergan to utilize business records as necessary within the scope of his
current employment. 
 11.    Allergan waives and shall not assert any defenses Allergan may have to any
criminal prosecution or administrative action relating to the Covered Conduct that may be based in whole or in part on a contention that, under the Double Jeopardy Clause in the Fifth Amendment of the Constitution, or under the Excessive Fines
Clause in the Eighth Amendment of the Constitution, this Agreement bars a remedy sought in such criminal prosecution or administrative action. Nothing in this paragraph or any other provision of this Agreement constitutes an agreement by the United
States concerning the characterization of the Settlement Amount for purposes of the Internal Revenue laws, Title 26 of the United States Code. 
  

 -14- 

 12.    Allergan fully and finally releases the United States, its
agencies, employees, servants, and agents from any claims (including attorneys’ fees, costs, and expenses of every kind and however denominated) that Allergan has asserted, could have asserted, or may assert in the future against the United
States, its agencies, employees, servants, and agents, related to the Covered Conduct or arising from the United States’ investigation and prosecution of the Civil Actions and the Criminal Action. 

13.    Conditioned upon Relators’ compliance with their obligations under this Agreement, Allergan, for itself,
its predecessors, and its current and former divisions, parents, affiliates, subsidiaries, successors, and assigns, and their current and former officers, directors, trustees, agents, servants, employees, representatives, attorneys, consultants,
executors, and administrators, when acting on behalf of Allergan or any of its affiliated companies, fully and finally releases and forever discharges Relators and their heirs, successors, attorneys, agents, and assigns (collectively, “Relator
Releasees”) from any and all claims for relief, actions, rights, causes of action, suits, debts, obligations, liabilities, demands, losses, damages (including treble damages and any civil penalties), punitive damages, costs, and expenses of any
kind, character, or nature whatsoever, known or unknown, fixed or contingent, in law or in equity, in contract or in tort, or under any federal or state statute or regulation or otherwise that Allergan, its predecessors, or its current and former
divisions, parents, affiliates, subsidiaries, successors, or assigns may now have or claim to have against the Relator Releasees, arising in any way out of or connected in any way with the facts, claims, and circumstances alleged in, arising under,
or arising from the Civil Actions, or from any other past activities and actions of the Relator Releasees, except to the extent related to: (1) claims Relators may have under 31 U.S.C. § 3730(d); (2) claims for a Relators’ Share
under the Medicaid State Settlement Agreements; or (3) 
  

 -15- 

 
any employment discrimination claim that Albert Edward Hallivis may have against Allergan, or rights Allergan may have arising out of any violation by him of the terms and conditions of his
employment. Allergan attests that, upon inquiry of its Legal Department, it is not presently aware of any claims its officers, directors, employees, or agents may have against Relator Releasees. 

14.    The Settlement Amount shall not be decreased as a result of the denial of claims for payment now being
withheld from payment by any Medicare carrier or intermediary or any other state or Federal payer, related to the Covered Conduct; and Allergan agrees not to resubmit to any Medicare carrier or intermediary or any other state or Federal payer any
previously denied claims related to the Covered Conduct, and agrees not to appeal any such denials of claims. 

15.    Allergan agrees to the following: 

(a)    Unallowable Costs Defined: that all costs (as defined in the Federal Acquisition Regulation, 48 C.F.R.
§ 31.205-47; and in Titles XVIII and XIX of the Social Security Act, 42 U.S.C. §§ 1395-1395hhh and 1396-1396v; and the regulations and official program directives promulgated thereunder) incurred by or on behalf of Allergan, its
present or former officers, directors, employees, shareholders, and agents in connection with the following shall be “Unallowable Costs” on government contracts and under the Medicare Program, Medicaid Program, TRICARE Program, and FEHBP:

  

	 	(i)	the matters covered by this Agreement and any related plea agreement; 

  

	 	(ii)	the United States’ audit(s) and civil and criminal investigation(s) of the matters covered by this Agreement; 

 

	 	(iii)	 Allergan’s investigation, defense, and corrective actions undertaken in response to the United States’ audit(s) and civil and criminal

  

 -16- 

	 	 
investigation(s) in connection with the matters covered by this Agreement (including attorneys’ fees); 

 

	 	(iv)	the negotiation and performance of this Agreement, the Plea Agreement, and the Medicaid State Settlement Agreements; 

 

	 	(v)	the payments Allergan makes to the United States pursuant to this Agreement, the Plea Agreement, or the Medicaid State Settlement Agreements, and any payments that
Allergan may make to Relators (including costs and attorneys’ fees); and 

  

	 	(vi)	the negotiation of, and obligations undertaken pursuant to the CIA to: 

  

	 	(a)	retain an independent review organization to perform annual reviews as described in Section III of the CIA; and 

 

	 	(b)	prepare and submit reports to the OIG-HHS. 

However, nothing in this Paragraph 15.a.vi. that may apply to the obligations undertaken pursuant to the CIA affects the status of costs
that are not allowable based on any other authority applicable to Allergan. (All costs described or set forth in this Paragraph 15.a. are hereafter “Unallowable Costs.”) 

(b)        Future Treatment of Unallowable Costs: These Unallowable Costs shall be
separately determined and accounted for by Allergan, and Allergan shall not charge such Unallowable Costs directly or indirectly to any contracts with the United States or any State Medicaid program, or seek payment for such Unallowable Costs
through any cost report, cost statement, information statement, or payment request submitted by Allergan or any of its subsidiaries or affiliates to the Medicare, Medicaid, TRICARE, or FEHBP Programs. 

(c)        Treatment of Unallowable Costs Previously Submitted for Payment: Allergan

  

 -17- 

 
further agrees that within 90 days of the Effective Date of this Agreement it shall identify to applicable Medicare and TRICARE fiscal intermediaries, carriers, and/or contractors, and Medicaid
and FEHBP fiscal agents, any Unallowable Costs (as defined in this Paragraph) included in payments previously sought from the United States, or any State Medicaid program, including, but not limited to, payments sought in any cost reports, cost
statements, information reports, or payment requests already submitted by Allergan or any of its subsidiaries or affiliates, and shall request, and agree, that such cost reports, cost statements, information reports, or payment requests, even if
already settled, be adjusted to account for the effect of the inclusion of the unallowable costs. Allergan agrees that the United States, at a minimum, shall be entitled to recoup from Allergan any overpayment plus applicable interest and penalties
as a result of the inclusion of such Unallowable Costs on previously-submitted cost reports, information reports, cost statements, or requests for payment. 

Any payments due after the adjustments have been made shall be paid to the United States pursuant to the direction of the Department of
Justice and/or the affected agencies. The United States reserves its rights to disagree with any calculations submitted by Allergan or any of its subsidiaries or affiliates on the effect of inclusion of Unallowable Costs (as defined in this
Paragraph) on Allergan or any of its subsidiaries or affiliates’ cost reports, cost statements, or information reports. 

(d)        Nothing in this Agreement shall constitute a waiver of the rights of the United States
to audit, examine, or re-examine Allergan’s books and records to determine that no Unallowable Costs have been claimed in accordance with the provisions of this Paragraph. 

16.        This Agreement is intended to be for the benefit of the Parties only. The Parties do
not release any claims against any other person or entity, except as explicitly stated in this 
  

 -18- 

 
Agreement, including in Paragraph 17 (waiver for beneficiaries paragraph), below. 

17.        Allergan agrees that it waives and shall not seek payment for any of the health care
billings covered by this Agreement from any health care beneficiaries or their parents, sponsors, legally responsible individuals, or third party payors based upon the claims defined as Covered Conduct. 

18.        Allergan warrants that it has reviewed its financial situation and that it currently
is solvent within the meaning of 11 U.S.C. §§ 547(b)(3) and 548(a)(1)(B)(ii)(I), and shall remain solvent following payment to the United States of the Settlement Amount. Further, the Parties warrant that, in evaluating whether to execute
this Agreement, they (a) have intended that the mutual promises, covenants, and obligations set forth herein constitute a contemporaneous exchange for new value given to Allergan, within the meaning of 11 U.S.C. § 547(c)(1); and
(b) conclude that these mutual promises, covenants, and obligations do, in fact, constitute such a contemporaneous exchange. Further, the Parties warrant that the mutual promises, covenants, and obligations set forth herein are intended to and
do, in fact, represent a reasonably equivalent exchange of value that is not intended to hinder, delay, or defraud any entity to which Allergan was or became indebted to on or after the date of this transfer, within the meaning of 11 U.S.C. §
548(a)(1). 
 19.        Within seven (7) days of making the payments described in
Paragraph 1, above, Allergan shall file a stipulation of dismissal with prejudice in the D.C. Litigation. 

20.        Upon the Effective Date of this Agreement, the United States shall file in Civil
Action III a Notice of Intervention as to the Covered Conduct. Upon receipt of the payments described in Paragraph 1, above, and entry of an order dismissing the D.C. Litigation with prejudice, the United States and Relators shall file a Joint
Stipulation of Dismissal in each of the 
  

 -19- 

 
Civil Actions as follows: 

(a)        each stipulation of dismissal shall be with prejudice as to the United States’
and Relators’ claims as to Allergan as to the Covered Conduct in each Civil Action pursuant to and consistent with the terms and conditions of this Agreement; 

(b)        each stipulation of dismissal shall be without prejudice to the United States and
with prejudice as to Relators as to all other claims; and 
 (c)        provided,
however, that the following claims against Allergan shall not be dismissed until they are settled, adjudicated, or otherwise resolved, and the Court is so informed: (a) Relators’ claims for reasonable attorneys’ fees, expenses, and
costs pursuant to 31 U.S.C. § 3730(d); (b) Relators’ claims for a Relators’ Share under the Medicaid State Settlement Agreements; and (c) any employment discrimination claims that Albert Edward Hallivis may have against
Allergan. 
 21.        Except as expressly provided to the contrary in this Agreement,
each Party shall bear its own legal and other costs incurred in connection with this matter, including the preparation and performance of this Agreement. 

22.        Allergan represents that this Agreement is freely and voluntarily entered into without
any degree of duress or compulsion whatsoever. 
 23.        Relators represent that
this Agreement is freely and voluntarily entered into without any degree of duress or compulsion whatsoever. 

24.        This Agreement is governed by the laws of the United States. The Parties agree that
the exclusive jurisdiction and venue for any dispute arising between and among the Parties under this Agreement is the United States District Court for the Northern District of Georgia, except that disputes arising under the CIA shall be resolved
exclusively under the dispute 
  

 -20- 

 
resolution provisions in the CIA. 

25.        For purposes of construction, this Agreement shall be deemed to have been drafted by
all Parties to this Agreement and shall not, therefore, be construed against any Party for that reason in any subsequent dispute. 

26.        This Agreement constitutes the complete agreement between the Parties. This Agreement
may not be amended except by written consent of the Parties. 
 27.        The
individuals signing this Agreement on behalf of Allergan represent and warrant that they are authorized by Allergan to execute this Agreement. The individuals signing this Agreement on behalf of Relators represent and warrant that they are
authorized by Relators to execute this Agreement. The United States signatories represent that they are signing this Agreement in their official capacities and that they are authorized to execute this Agreement. 

28.        This Agreement may be executed in counterparts, each of which constitutes an original
and all of which constitute one and the same Agreement. 
 29.        This Agreement is
binding on Allergan’s successors, transferees, heirs, attorneys, agents, and assigns. 

30.        This Agreement is binding on Relators’ successors, transferees, heirs, attorneys,
agents, and assigns. 
 31.        All parties consent to the United States’
disclosure of this Agreement, and information about this Agreement, to the public. 

32.        This Agreement is effective on the date of signature of the last signatory to the
Agreement (Effective Date of this Agreement). Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this Agreement. 
  

 -21- 

 THE UNITED STATES OF AMERICA 

 

													
	DATED:	 	     8/31/10
	 		 	BY:	 	     /s/ Sally Quillian Yates
	  		 	
		 		 		 		 	SALLY QUILLIAN YATES	 	
		 		 		 		 	United States Attorney	 	
		 		 		 		 	United States Attorney’s Office	 	
		 		 		 		 	Northern District of Georgia	 	
							
	DATED:	 	     8/31/10
	 		 	BY:	 	     /s/ Amy Berne
	  		 	
		 		 		 		 	AMY BERNE	 	
		 		 		 		 	Chief, Civil Division	 	
		 		 		 		 	United States Attorney’s Office	 	
		 		 		 		 	Northern District of Georgia	 	
							
	DATED:	 	     8/31/10
	 		 	BY:	 	     /s/ Sally B. Molloy
	  		 	
		 		 		 		 	SALLY B. MOLLOY	 	
		 		 		 		 	Assistant U.S. Attorney	 	
		 		 		 		 	United States Attorney’s Office	 	
		 		 		 		 	Northern District of Georgia	 	
							
	DATED:	 	     8/31/2010
	 		 	BY:	 	     /s/ Christopher J. Huber
	  		 	
		 		 		 		 	CHRISTOPHER J. HUBER	 	
		 		 		 		 	Assistant U.S. Attorney	 	
		 		 		 		 	United States Attorney’s Office	 	
		 		 		 		 	Northern District of Georgia	 	
							
	DATED:	 	     8/31/10
	 		 	BY:	 	     /s/ Edward C. Crooke
	  		 	
		 		 		 		 	EDWARD C. CROOKE	 	
		 		 		 		 	Trial Attorney	 	
		 		 		 		 	Commercial Litigation Branch	 	
		 		 		 		 	Civil Division	 	
		 		 		 		 	United States Department of Justice	 	

  

 -22- 

													
	DATED:	 	     8/20/10
	 		 	BY:	 	     /s/ Gregory E. Demske
	 		 	
		 		 		 		 	GREGORY E. DEMSKE	 	
		 		 		 		 	Assistant Inspector General for Legal Affairs	 	
		 		 		 		 	Office of Counsel to the Inspector General	 	
		 		 		 		 	Office of Inspector General	 	
		 		 		 		 	United States Department of Health and Human Services	 	
							
	DATED:	 	     18 Aug 2010
	 		 	BY:	 	     /s/ Laurel C. Gillespie
	 		 	
		 		 		 		 	LAUREL C. GILLESPIE	 	
		 		 		 		 	Deputy General Counsel	 	
		 		 		 		 	TRICARE Management Activity	 	
		 		 		 		 	United States Department of Defense	 	
							
	DATED:	 	     8/18/10
	 		 	BY:	 	     /s/ Shirley R. Patterson
	 		 	
		 		 		 		 	SHIRLEY R. PATTERSON	 	
		 		 		 		 	Acting Deputy Associate Director Insurance Operations	 	
		 		 		 		 	United States Office of Personnel Management	 	
							
	DATED:	 	     8/19/2010
	 		 	BY:	 	     /s/ J. David Cope
	 		 	
		 		 		 		 	J. DAVID COPE	 	
		 		 		 		 	Assistant Inspector General for Legal Affairs	 	
		 		 		 		 	United States Office of Personnel Management	 	
							
	DATED:	 	     8/18/2010
	 		 	BY:	 	     /s/ Cecily A. Rayburn
	 		 	
		 		 		 		 	 CECILY A. RAYBURN
	 	
		 		 		 		 	Acting Deputy Director	 	
		 		 		 		 	Office of Workers’ Compensation Programs	 	
		 		 		 		 	United States Department of Labor	 	

  

 -23- 

 ALLERGAN 

 

									
	 DATED:
	 	     8/30/10
	 	BY:	 	     /s/ Samuel J. Gesten
	 	
		 		 		 	SAMUEL J. GESTEN, ESQ.
		 		 		 	Executive Vice President and General Counsel
		 		 		 	Allergan, Inc.
				
		 		 		 	Vice President and Assistant Secretary
		 		 		 	Allergan USA, Inc.
					
	 DATED:
	 	     8/31/10
	 	BY:	 	     /s/ Stephen S. Cowen
	 	
		 		 		 	STEPHEN S. COWEN, ESQ.	 	
		 		 		 	King & Spalding, LLP	 	
					
	 DATED:
	 	     8/31/10
	 	BY:	 	     /s/ Matthew H. Baughman
	 	
		 		 		 	MATTHEW H. BAUGHMAN, ESQ.
		 		 		 	King & Spalding, LLP
					
	 DATED:
	 	     8/31/10
	 	BY:	 	     /s/ John T. Bentivoglio
	 	
		 		 		 	JOHN T. BENTIVOGLIO, ESQ.
		 		 		 	Skadden, Arps, Slate, Meagher & Flom, LLP

  

 -24- 

 RELATOR AMY M. LANG, M.D. 

 

									
	DATED:	 	     8/18/2010
	 	BY:	 	     /s/ Amy M. Lang, M.D.
	 	
		 		 		 	AMY M. LANG, M.D.	 	
					
	DATED:	 	     08/18/10
	 	BY:	 	     /s/ John E. Floyd
	 	
		 		 		 	JOHN E. FLOYD, ESQ.	 	
		 		 		 	Bondurant, Mixson, & Elmore, LLP	 	
					
	DATED:	 	     08/18/10
	 	BY:	 	     /s/ Ben E. Fox
	 	
		 		 		 	BEN E. FOX, ESQ.	 	
		 		 		 	Bondurant, Mixson, & Elmore, LLP	 	
					
	DATED:	 	     8/18/2010
	 	BY:	 	     /s/ Lance D. Lourie
	 	
		 		 		 	LANCE D. LOURIE, ESQ.	 	
		 		 		 	Watkins, Lourie, Roll & Chance, P.C.	 	

  

 -25- 

 RELATOR CHARLES J. RUSHIN 

 

									
	DATED:	 	     8/18/2010
	 	BY:	 	     /s/ Charles J. Rushin
	 	
		 		 		 	CHARLES J. RUSHIN	 	
					
	DATED:	 	     08/18/2010
	 	BY:	 	     /s/ John E. Floyd
	 	
		 		 		 	JOHN E. FLOYD, ESQ.	 	
		 		 		 	Bondurant, Mixson, & Elmore, LLP	 	
					
	DATED:	 	     08/18/10
	 	BY:	 	     /s/ Ben E. Fox
	 	
		 		 		 	BEN E. FOX, ESQ.	 	
		 		 		 	Bondurant, Mixson, & Elmore, LLP	 	
					
	DATED:	 	     8/18/10
	 	BY:	 	     /s/ Lance D. Lourie
	 	
		 		 		 	LANCE D. LOURIE, ESQ.	 	
		 		 		 	Watkins, Lourie, Roll & Chance, P.C.	 	

  

 -26- 

 RELATOR CHER BEILFUSS 

 

									
	 DATED:
	 	     Aug 22, 2010
	 	BY:	 	     /s/ Cher Beilfuss
	 	
		 		 		 	CHER BEILFUSS	 	
					
	 DATED:
	 	     8/23/10
	 	BY:	 	     /s/ Marcella Auerbach
	 	
		 		 		 	MARCELLA AUERBACH, ESQ.	 	
		 		 		 	Nolan & Auerbach, P.A.	 	
					
	 DATED:
	 	     8/23/10
	 	BY:	 	     /s/ Ken Nolan
	 	
		 		 		 	KEN NOLAN, ESQ.	 	
		 		 		 	Nolan & Auerbach, P.A.	 	

  

 -27- 

 RELATOR KATHLEEN O’CONNOR-MASSE 

 

									
	DATED:	 	     8/18/10
	 	BY:	 	     /s/ Kathleen O’Connor-Masse
	 	
		 		 		 	KATHLEEN O’CONNOR-MASSE	 	
					
	DATED:	 	     8/23/10
	 	BY:	 	     /s/ Marcella Auerbach
	 	
		 		 		 	MARCELLA AUERBACH, ESQ.	 	
		 		 		 	Nolan & Auerbach, P.A.	 	
					
	DATED:	 	     8/23/10
	 	BY:	 	     /s/ Ken Nolan
	 	
		 		 		 	KEN NOLAN, ESQ.	 	
		 		 		 	Nolan & Auerbach, P.A.	 	

  

 -28- 

 RELATOR ALBERT EDWARD HALLIVIS 

 

									
	DATED:	 	     8/18/10
	 	BY:	 	     /s/ Albert Edward Hallivis
	 	
		 		 		 	ALBERT EDWARD HALLIVIS	 	
					
	DATED:	 	     8/18/10
	 	BY:	 	     /s/ Jay P. Holland
	 	
		 		 		 	JAY P. HOLLAND, ESQ.	 	
		 		 		 	Joseph, Greenwald & Laake, P.A.	 	
					
	DATED:	 	     8/18/10
	 	BY:	 	     /s/ Brian J. Markowitz
	 	
		 		 		 	BRIAN J. MARKOWITZ, ESQ.	 	
		 		 		 	Joseph, Greenwald & Laake, P.A.	 	

  

 -29-Exhibit 10.2

 Exhibit 10.2 

CORPORATE INTEGRITY AGREEMENT 

BETWEEN THE 

OFFICE OF INSPECTOR GENERAL 

OF THE 

DEPARTMENT OF HEALTH AND HUMAN SERVICES 

 AND 

ALLERGAN, INC. 
  

	I.	PREAMBLE 

Allergan, Inc. (Allergan) hereby enters into this Corporate Integrity Agreement (CIA) with the Office of Inspector General (OIG) of the
United States Department of Health and Human Services (HHS) to promote compliance with the statutes, regulations, and written directives of Medicare, Medicaid, and all other Federal health care programs (as defined in 42 U.S.C. § 1320a-7b(f))
(Federal health care program requirements) and with the statutes, regulations, and written directives of the Food and Drug Administration (FDA requirements). Contemporaneously with this CIA, Allergan is entering into a Settlement Agreement with the
United States. Allergan will also enter into settlement agreements with various States (State Settlement Agreements) and Allergan’s agreement to this CIA is a condition precedent to those agreements. 

Prior to the Effective Date, Allergan established a voluntary compliance program (Compliance Program) and initiated certain voluntary
compliance measures. Allergan shall continue its Compliance Program throughout the term of the CIA and shall do so in accordance with the terms set forth below. Allergan may modify its Compliance Program, as appropriate, but at a minimum, Allergan
shall ensure that during the term of this CIA, it shall comply with the obligations set forth in this CIA. 
  

	II.	TERM AND SCOPE OF THE CIA 

A. The effective date of this CIA shall be the date on which the final signatory executes this document (Effective Date). The period of
the compliance obligations assumed by Allergan under this CIA shall be five years from the Effective Date of this CIA, unless otherwise specified. Each one-year period, beginning with the one-year period following the first day of the first calendar
month following the Effective Date, shall be referred to as a “Reporting Period.” 
  

 1 

 B. Sections VII, X, and XI shall expire no later than 120 days after OIG’s receipt of:
(1) Allergan’s final Annual Report; or (2) any additional materials submitted by Allergan pursuant to OIG’s request, whichever is later. 

C. The scope of this CIA shall be governed by the following definitions: 

 

	 	1.	“Covered Persons” includes: 

a. all owners of Allergan and any Allergan Affiliate (as defined below) who are natural persons (other than shareholders who:
(1) have an ownership interest of less than 5% and (2) acquired the ownership interest through public trading); 
 b.
all officers, directors, and employees of Allergan or any Allergan Affiliate, who are: 1) based in the United States, or 2) based outside the United States and who have responsibilities relating to Promotional Functions or Product Related Functions,
except as carved out below in this Section II.C.1; and 
 c. all contractors, subcontractors, agents, and other persons who
perform Promotional Functions or Product Related Functions in the United States on behalf of Allergan or any Allergan Affiliate. 

Notwithstanding the above, the term “Covered Persons” does not include: (i) employees, contractors, subcontractors, agents
or other personnel of Allergan, or any Allergan Affiliate, who perform only manufacturing or building and facilities functions (i.e., facilities maintenance, grounds maintenance, and food services functions), so long as such personnel do not
have responsibilities relating to Promotional Functions or Product Related Functions; and (ii) part-time or per diem employees, contractors, subcontractors, agents, and other persons who are not reasonably expected to work more than 160 hours
per year, except that any such individuals shall become “Covered Persons” at the point when they work more than 160 hours during the calendar year. 
  

 2 

	 	2.	“Relevant Covered Persons” includes all Covered Persons whose job responsibilities relate to Promotional Functions or Product Related Functions.

  

	 	3.	“Government Reimbursed Products” refers to all Allergan human pharmaceutical products promoted or sold by Allergan or any Allergan Affiliate in the United
States or pursuant to contracts with the United States that are reimbursed by Federal health care programs. 

  

	 	4.	The term “Promotional Functions” includes: (a) the selling, detailing, marketing, advertising, promoting, or branding of Government Reimbursed Products;
and (b) the preparation, or external dissemination of promotional materials or information about, or the provision of promotional services relating to, Government Reimbursed Products, including those functions relating to any applicable review
committees. 

  

	 	5.	The term “Product Related Functions” includes: (a) the preparation or external dissemination of non-promotional materials that are governed by Federal
health care program and/or FDA requirements and distributed to healthcare professionals (HCPs) and healthcare institutions (HCIs) about Government Reimbursed Products, including those functions relating to any applicable review committees and
Allergan’s Medical Affairs Department (Medical Affairs); (b) contracting with HCPs in the United States to conduct post-marketing clinical trials and other post-marketing studies (including Investigator-Initiated Trials (IITs)) relating to
Government Reimbursed Products; (c) authorship, publication, and disclosure of articles or study results relating to Government Reimbursed Products; and (d) activities related to the submission of information about Government Reimbursed
Products in government-listed compendia (such as DrugDex or other compendia of information about Government Reimbursed Products). 

  

	 	6.	 The term “Third Party Personnel” shall mean personnel who perform Promotional Functions or Product Related Functions who are employees of
entities with whom Allergan or any Allergan Affiliate has or may in the future (during the term of this CIA) enter into agreements to co-promote 

 

 3 

	 	 
a Government Reimbursed Product in the United States. Allergan has represented that: 1) Third Party Personnel are employed by entities other than Allergan or any Allergan Affiliate; 2) neither
Allergan nor any Allergan Affiliate controls the Third Party Personnel; and (3) it would be commercially impracticable to compel the compliance of Third Party Personnel with the requirements set forth in this CIA. Allergan agrees that Allergan
and Allergan Affiliates shall promote compliance by Third Party Personnel with Federal health care program and FDA requirements by complying with the provisions set forth below in Sections III.B.2, V.A.7 and V.B.7. Provided that Allergan complies
with the requirements of Sections III.B.2, V.A.7 and V.B.7, Allergan shall not be required to fulfill the other CIA obligations that would otherwise apply to Third Party Personnel who meet the definition of Covered Persons.

  

	 	7.	The term “Third Party Educational Activity” shall mean any continuing medical education (CME), or other scientific, educational, or professional program,
meeting, or event supported conducted by a third party in the U.S. and supported by Allergan, or an Allergan Affiliate, including but not limited to, sponsorship of symposia at medical conferences. 

 

	 	8.	The term “Allergan Affiliate” shall mean any entity that is controlled, directly or indirectly, through ownership or otherwise, by Allergan and whose
employees or contractors perform Promotional Functions or Product Related Functions. The term Allergan Affiliates includes, but is not limited to, the following entities: Allergan USA Inc., Allergan Sales LLC, and Pacific Communications.

  

	III.	CORPORATE INTEGRITY OBLIGATIONS  

Allergan shall establish and maintain a Compliance Program throughout the term of this CIA that includes the following elements:

  

 4 

 A. Compliance Responsibilities of Certain Allergan Employees and the Board.

 1. Chief Compliance Officer. Prior to the Effective Date, Allergan appointed a Chief Compliance Officer and Allergan
shall maintain a Chief Compliance Officer during the term of the CIA. During the term of the CIA, the Chief Compliance Officer shall be authorized to oversee compliance with regard to Allergan’s U.S. operations, with Federal health care program
and FDA requirements, and with the requirements of this CIA. The Chief Compliance Officer shall be responsible for developing and implementing policies, procedures, and practices designed to ensure compliance with the requirements set forth in this
CIA and with Federal health care program requirements and FDA requirements. The Chief Compliance Officer shall be a member of senior management of Allergan, shall report directly to the Chief Executive Officer of Allergan, shall make periodic (at
least quarterly) reports regarding compliance matters directly to the Board of Directors of Allergan or a Committee of the Board of Directors of Allergan (the term “Board” shall mean such Board of Directors or Committee thereof), and shall
be authorized to report on such matters to the Chief Executive Officer of Allergan and the Board at any time. The Chief Compliance Officer shall not be, or be subordinate to, the General Counsel or Chief Financial Officer. The Chief Compliance
Officer shall be responsible for monitoring the day-to-day compliance activities engaged in by Allergan as well as for any reporting obligations created under this CIA. Any noncompliance job responsibilities of the Chief Compliance Officer shall be
limited and must not interfere with the Compliance Officer’s ability to perform the duties outlined in this CIA. 

Allergan shall report to OIG, in writing, any change in the identity of the Chief Compliance Officer, or any actions or changes that
would affect the Chief Compliance Officer’s ability to perform the duties necessary to meet the obligations in this CIA, within five days after the change. 

2. U.S. Compliance Committee. Prior to the Effective Date, Allergan established a Compliance Committee that addressed U.S.
compliance issues, and Allergan shall maintain a U.S. Compliance Committee during the term of this CIA. The U.S. Compliance Committee shall, at a minimum, include the Chief Compliance Officer and other members of senior management necessary to meet
the requirements of this CIA (e.g., senior executives of relevant departments). The Chief Compliance Officer shall chair the U.S. Compliance Committee, and the U.S. Compliance Committee shall support the Chief Compliance Officer in fulfilling
his/her responsibilities under the CIA (e.g., 
  

 5 

 
shall assist in the analysis of the organization’s risk areas and shall oversee monitoring of internal and external audits and investigations). The U.S. Compliance Committee shall meet at
least quarterly. 
 Allergan shall report to OIG, in writing, any changes in the composition of the U.S. Compliance Committee,
or any actions or changes that would affect the U.S. Compliance Committee’s ability to perform the duties necessary to meet the obligations in this CIA, within 15 days after such a change. 

3.        Board Compliance Obligations. The Board of Allergan shall be responsible for
the review and oversight of matters related to compliance with Federal health care program requirements, FDA requirements, and the obligations of this CIA. The Board shall, at a minimum, be responsible for the following: 

a. The Board shall meet at least quarterly to review and oversee Allergan’s Compliance Program, including but not limited to
evaluating its effectiveness and receiving updates about the activities of the Chief Compliance Officer and other compliance personnel. 

b. For each Reporting Period, the Board shall adopt a resolution, and the resolution shall be signed by each individual member of the
Board, summarizing its review and oversight of matters relating to Allergan’s compliance with Federal health care program requirements, FDA requirements, and the obligations of this CIA. 

At minimum, the resolution shall include the following language: 

“The Board of Directors [or a Committee of the Board] has made a reasonable inquiry into the operations of Allergan’s
Compliance Program for the period             , including but not limited to evaluating its effectiveness and receiving updates about the activities of its Chief Compliance Officer
and other compliance personnel. Based on its inquiry, the Board [or the Committee] has concluded that, to the best of its knowledge, Allergan has implemented an effective Compliance Program to meet Federal health care program requirements, FDA
requirements, and the obligations of the CIA.” 
  

 6 

 If the Board is unable to provide such a conclusion in the resolution, the Board shall
include in the resolution a written explanation of the reasons why it is unable to provide the conclusion and the steps it is taking to assure implementation by Allergan of an effective Compliance Program at Allergan. 

Allergan shall report to OIG, in writing, any changes in the composition of the Board, or changes that would affect the Board’s
ability to perform the duties necessary to meet the obligations in this CIA, within 15 days after such a change. 

4.        Management Accountability and Certifications: In addition to the
responsibilities set forth in this CIA for all Covered Persons, certain Allergan employees (“Certifying Employees”) are specifically expected to monitor and oversee activities within their areas of authority and shall annually certify, in
writing or electronically, that the applicable Allergan component is compliant with Federal health care program requirements, FDA requirements, and the obligations of this CIA. These Certifying Employees shall include, at a minimum, the following
individuals from Allergan: Chief Executive Officer; President; Corporate Vice President, North America; Corporate Vice President, Allergan Medical; Corporate Vice President, Global Marketing; Vice President, Medical Affairs; Vice President, Managed
Markets; and the Vice Presidents of U.S. Dermatology Sales and Marketing; U.S. Managed Markets; U.S. Eye Care Sales and Marketing; U.S. Neurosciences Sales and Marketing; U.S. Commercial Operations; Health Sales and Marketing; Facial Aesthetics
Sales and Marketing; Breast Aesthetics Sales and Marketing; and Global Strategic Marketing. 
 For each Reporting Period, each
Certifying Employee shall sign a certification that states: 
 “I have been trained on and understand the compliance
requirements and responsibilities as they relate to [department or functional area], an area under my supervision. My job responsibilities include monitoring and oversight of compliance with regard to the
             [insert name of the department or functional area]. To the best of my knowledge, except as otherwise described herein, the
                     [insert name of department or functional area] of Allergan is in compliance with all applicable Federal health care
program requirements, FDA requirements, and the obligations of the CIA.” 
  

 7 

 If any Certifying Employee is unable to provide such a conclusion in the certification, the
Certifying Employee shall provide a written explanation of the reasons why he or she is unable to provide make the certification outlined above and the steps being taken to address the issue(s) identified in the certification. 

B. Written Standards. 

1. Code of Conduct. Prior to the Effective Date, Allergan developed, implemented, and distributed a written Code of Conduct to
all Covered Persons who are employees. Allergan shall make the promotion of, and adherence to, the Code of Conduct a condition of employment of all Covered Persons who are employees. 

The Code of Conduct sets forth and shall continue to set forth, at a minimum, the following: 

a. Allergan’s commitment to full compliance with all Federal health care program and FDA requirements, including its commitment to
market, sell, promote, research, develop, provide information about, and advertise its products in accordance with Federal health program requirements and FDA requirements; 

b. Allergan’s requirement that all of its Covered Persons shall be expected to comply with all Federal health care program and FDA
requirements and with Allergan’s own Policies and Procedures as implemented pursuant to Section III.B (including the requirements of this CIA); 

c. Allergan’s requirement that all of Allergan’s Covered Persons shall be expected to report to the Chief Compliance Officer,
or other appropriate individual designated by Allergan, suspected violations by Allergan or persons acting on behalf of Allergan of any Federal health care program and FDA requirements or of Allergan’s own Policies and Procedures; and

 d. the right of individuals to use the Disclosure Program described in Section III.E, and Allergan’s commitment to
nonretaliation and to 
  

 8 

 
maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. 

To the extent not already accomplished within the last 150 days, within 120 days after the Effective Date, the Code of Conduct shall be
distributed to each Covered Person and each Covered Person shall certify, in writing or electronically, that he or she has received, read, understood, and shall abide by Allergan’s Code of Conduct. New Covered Persons shall receive the Code of
Conduct and shall complete the required certification within 30 days after becoming a Covered Person or within 120 days after the Effective Date, whichever is later. 

Allergan shall periodically review the Code of Conduct to determine if revisions are appropriate and shall make any necessary revisions
based on such review. Any revised Code of Conduct shall be distributed within 30 days after any revisions are finalized by the Corporate Compliance Department. Each Covered Person shall certify, in writing or electronically, that he or she has
received, read, understood, and shall abide by the revised Code of Conduct within 30 days after the distribution of the revised Code of Conduct. 

2. Third Party Personnel. Within 150 days after the Effective Date, and annually thereafter by the anniversary of the Effective
Date, Allergan and/or the Allergan Affiliate shall send a letter to each entity employing Third Party Personnel. The letter shall outline Allergan’s obligations under the CIA and its commitment to full compliance with all Federal health care
program and FDA requirements. The letter shall include a description of Allergan’s Compliance Program. Allergan and/or the Allergan Affiliate shall attach a copy of its Code of Conduct to the letter and shall request the entity employing Third
Party Personnel to either: (a) make a copy of Allergan’s Code of Conduct and a description of Allergan’s Compliance Program available to its Third Party Personnel; or (b) represent to Allergan and/or the Allergan Affiliate that
it has and enforces a substantially comparable code of conduct and compliance program for its Third Party Personnel. 
 3.
Policies and Procedures. Prior to the Effective Date, Allergan implemented written Policies and Procedures regarding the operation of the Compliance Program and Allergan’s compliance with Federal health care program and FDA requirements
(Policies and Procedures). To the extent not already accomplished, within 
  

 9 

 
150 days after the Effective Date, Allergan shall ensure that the Policies and Procedures address or shall continue to address: 

 

	 	a.	the subjects relating to the Code of Conduct identified in Section III.B.1; 

 

	 	b.	appropriate ways to conduct Promotional Functions, including sponsorships, in compliance with all applicable Federal healthcare program requirements, including, but not
limited to the Federal anti-kickback statute (codified at 42 U.S.C. § 1320a-7b(b)), and the False Claims Act (codified at 31 U.S.C. §§ 3729-3733); 

 

	 	c.	appropriate ways to conduct Product Related Functions in compliance with all applicable Federal healthcare program requirements, including, but not limited to the
Federal anti-kickback statute (codified at 42 U.S.C. § 1320a-7b(b)), and the False Claims Act (codified at 31 U.S.C. §§ 3729-3733); 

  

	 	d.	appropriate ways to conduct Promotional Functions in compliance with all applicable FDA requirements; 

 

	 	e.	appropriate ways to conduct Product Related Functions in compliance with all applicable FDA requirements; 

 

	 	f.	 appropriate ways to provide reimbursement support services in compliance with all applicable Federal health care program requirements. The Policies and
Procedures shall be designed to ensure that Allergan’s provision of reimbursement support services complies with all applicable Federal health care program and FDA requirements. The Policies and Procedures shall require appropriate qualified
Allergan legal and other personnel to review Allergan’s policies, procedures, and practices relating to the provision of reimbursement support services (including the compliance controls relating to the provision of such services) on at least
an annual basis. If Allergan determines, through its review, that its policies, procedures, and/or practices relating to 

 

 10 

	 	 
reimbursement support services are not in compliance with applicable Federal health care program and FDA requirements, Allergan shall modify its policies, procedures, and/or practices to ensure
compliance with all applicable Federal health care program and FDA requirements; 

  

	 	g.	the materials and information that may be distributed by Allergan sales representatives about Allergan’s Government Reimbursed Products and the manner in which
Allergan sales representatives respond to requests for information about non-FDA approved (or “off-label”) uses of Allergan’s Government Reimbursed Products. As of the Effective Date, Allergan’s Policies and Procedures required
that sales representatives refer all requests for information about off-label uses of Allergan’s Government Reimbursed Products to Medical Affairs; 

  

	 	h.	the materials and information that may be distributed by Medical Affairs and the mechanisms through, and manner in which, Medical Affairs receives and responds to
requests for information submitted by sales representatives about off-label uses of Allergan’s Government Reimbursed Products; the form and content of information disseminated by Allergan in response to such requests; and the internal review
process for the information disseminated. These Policies and Procedures shall also require that distribution of any reprints of medical journal articles must be consistent with applicable FDA requirements; 

The Policies and Procedures shall include a requirement that Medical Information (a subdivision of Medical Affairs) develop database(s)
to track all requests for information about Allergan’s Government Reimbursed Products to Medical Information. This database shall be referred to as the “Inquiries Database.” The Inquiries Database shall include the following items of
information for each unique inquiry (Inquiry) received for information about Allergan’s products: 1) date of Inquiry; 2) form of Inquiry (e.g., fax, phone, etc.); 3) name of the requesting health care professional (HCP) or health care
institution (HCI) in 
  

 11 

 
accordance with applicable privacy laws; 4) nature and topic of request (including exact language of the Inquiry if made in writing); 5) nature/form of the response from Allergan (including a
record of the materials provided to the HCP or HCI in response to the request); and 6) the name of the Allergan representative who called on or interacted with the HCP or HCI, if known; 

 

	 	i.	the manner and circumstances under which medical personnel from Medical Affairs participate in meetings or events with HCPs or HCIs (either alone or with sales
representatives or account executives) and the role of the medical personnel at such meetings or events, as well as how they handle responses to unsolicited requests about off-label indications of Allergan’s Government Reimbursed Products;

  

	 	j.	the development, implementation, and review of plans for calling on and distributing samples to HCPs and HCIs (Call Plans), for sales representatives who promote
Government Reimbursed Products. For each Government Reimbursed Product, the Policies and Procedures shall require that Allergan review the Call Plans for the product and the bases upon, and circumstances under, which HCPs and HCIs belonging to
specified medical specialties or types of clinical practice are included in, or excluded from, the Call Plans. The Policies and Procedures shall also require that Allergan modify the Call Plans as necessary to ensure that Allergan is promoting its
Government Reimbursed Products in a manner that complies with all applicable Federal health care program and FDA requirements. The Call Plan reviews shall occur at least annually and shall also occur each time when the FDA approves a new or
additional indication for a Government Reimbursed Product; 

  

	 	k.	 the development, implementation, and review of policies for the distribution of samples of Allergan’s Government Reimbursed Products. This shall
include a review of the bases upon, and circumstances under, which HCPs and HCIs belonging to specified medical specialties or types of clinical practice may 

 

 12 

	 	 
receive samples from Allergan. The Policies and Procedures shall also require that Allergan modify the sample distribution policy as necessary to ensure that Allergan is promoting its products in
a manner that complies with all applicable Federal health care program and FDA requirements; 

  

	 	l.	consultant or other fee-for-service arrangements entered into with HCPs or HCIs (including, but not limited to speaker programs, speaker training programs,
presentations, consultant task force meetings, advisory boards, and ad hoc advisory activities, and any other financial engagement or arrangement with an HCP or HCI) and all events and expenses relating to such engagements or arrangements. These
Policies and Procedures shall be designed to ensure that the arrangements and related events are used for legitimate and lawful purposes in accordance with applicable Federal health care program and FDA requirements. The Policies and Procedures
shall include requirements about the content and circumstances of such arrangements and events; 

  

	 	m.	programs to educate sales representatives, including but not limited to presentations by HCPs at sales meetings and experience-based learning activities, if any. These
Policies and Procedures shall be designed to ensure that the programs are used for legitimate and lawful purposes in accordance with applicable Federal health care program and FDA requirements. The Policies shall include requirements about the
content and circumstances of such arrangements and events; 

  

	 	n.	sponsorship or funding of charitable contributions. These Policies and Procedures shall be designed to ensure that Allergan’s funding and/or sponsorship complies
with all applicable Federal health care program and FDA requirements; 

  

	 	o.	funding of grants (including educational grants) to HCPs and HCIs. These Policies and Procedures shall be designed to ensure that Allergan’s funding complies with
all applicable Federal health care program and FDA requirements; 

  

 13 

	 	p.	funding of, or participation in, any Third Party Educational Activity as defined in Section II.C.7 above. These Policies and Procedures shall be designed to ensure that
Allergan’s funding and/or sponsorship of such programs satisfies all applicable Federal health care program and FDA requirements. 

The Policies and Procedures shall require that: 1) Allergan disclose its financial support of the Third Party Educational Activity and,
to the extent feasible consistent with subsection III.B.3.p.5 below, any financial relationships with faculty, speakers, or organizers at such Activity; 2) as a condition of funding, the third party shall agree to disclose Allergan’s financial
support of the Third Party Educational Activity and any financial relationships that Allergan might have with faculty, speakers, or organizers at such Activity; 3) any faculty, speakers, or organizers at the Third Party Educational Activity disclose
any financial relationship with the applicable Allergan entity; 4) the Third Party Educational Activity have an educational focus; 5) the content, organization, and operation of the Third Party Educational Activity be independent of Allergan’s
control; 6) Allergan or the Allergan Affiliate support only Third Party Educational Activity that is non-promotional in tone/nature; and 7) Allergan’s or any Allergan Affiliate’s support of a Third Party Educational Activity shall be
contingent on the provider’s commitment to provide information at the Third Party Educational Activity that is fair, balanced, accurate and not misleading; 
  

	 	q.	 review of all promotional and written materials and information intended to be disseminated outside Allergan by appropriate qualified personnel (such
as regulatory, medical, and/or legal personnel) in a manner designed to ensure that legal, regulatory, and medical concerns are properly addressed during Allergan’s review and approval process and are elevated when appropriate. The Policies and
Procedures shall be designed to ensure that such materials and information comply with all applicable Federal 

 

 14 

	 	 
health care program and FDA requirements. The Policies and Procedures shall require that: 1) applicable review committees review all promotional materials prior to the distribution or use of such
materials; and 2) deviations from the standard review committee practices and protocols (including timetables for the review of materials) shall be documented and referred for appropriate follow-up; 

 

	 	r.	compensation (including through salaries, bonuses, and contests) for Relevant Covered Persons who are sales representatives. These Policies and Procedures shall: 1) be
designed to ensure that financial incentives do not inappropriately motivate such individuals to engage in improper promotion, sales, and marketing of Allergan’s Government Reimbursed Products; and 2) include mechanisms, where appropriate, to
exclude from incentive compensation sales that may indicate the off-label promotion of Allergan Government Reimbursed Products; 

  

	 	s.	the submission of information about any Government Reimbursed Product to any compendia such as DrugDex or other published source of information used in connection with
the determination of coverage by a Federal health care program for the Product (“Compendia”). This includes any initial submission of information to any Compendia and the submission of any additional, updated, supplemental, or changed
information (e.g., any changes based on Allergan’s discovery of erroneous or scientifically unsound information or data associated with the information in the Compendia.) The Policies and Procedures shall include a requirement that
Allergan conduct an annual review of all arrangements, processing fees, or other payments or financial support (if any) provided by the company to any Compendia. Allergan U.S. compliance personnel shall be involved in this review;

  

	 	t.	 the sponsorship of post-marketing clinical trials or other post-marketing studies (including IITs) including the decision to provide financial or other
support for such studies; the manner in 

  

 15 

	 	 
which support is provided; and support for publication of information about such studies, including the publication of information about the trial outcomes and results and the uses made of
publications relating to such studies; 

  

	 	u.	authorship of any articles or other publications about Government Reimbursed Products or about therapeutic areas or disease states that may be treated with Government
Reimbursed Products, including, but not limited to, the disclosure of any and all relationships between the author and Allergan or any Allergan Affiliate, the identification of all authors or contributors (including professional writers) associated
with a given publication, and the scope and breadth of research results made available to each author or contributor; and 

  

	 	v.	disciplinary policies and procedures for violations of Allergan’s Policies and Procedures, including policies relating to Federal health care program and FDA
requirements. 

 To the extent not already accomplished, within 150 days after the Effective Date, the relevant
portions of the Policies and Procedures shall be made available to all Covered Persons whose job functions relate to those Policies and Procedures. Appropriate and knowledgeable staff shall be available to explain the Policies and Procedures.

 At least annually (and more frequently, if appropriate), Allergan shall assess and update, as necessary, the Policies and
Procedures. Within 30 days after the effective date of any revisions, the relevant portions of any such revised Policies and Procedures shall be made available to all Covered Persons whose job functions relate to those Policies and Procedures.

 C. Training and Education. 

1. General Training. Within 150 days after the Effective Date, Allergan shall provide at least one hour of General Training to
each Covered Person. This training, at a minimum, shall explain Allergan’s: 
 a. CIA requirements; and 

 

 16 

 b. Compliance Program, including the Code of Conduct. 

New Covered Persons shall receive the General Training described above within 30 days after becoming a Covered Person or within 150 days
after the Effective Date, whichever is later. After receiving the initial General Training described above, each Covered Person shall receive at least one hour of General Training in each subsequent Reporting Period. 

2. Specific Training. 

Within 150 days after the Effective Date, each Relevant Covered Person engaged in Promotional Functions and/or Product Related Functions
shall receive at least three hours of Specific Training applicable to their specific job functions in addition to the General Training required above. This Specific Training shall include a discussion of: 

a. all applicable Federal health care program requirements relating to Promotional Functions and/or Product Related Functions;

 b. all applicable FDA requirements relating to Promotional Functions and/or Product Related Functions; 

c. all Allergan Policies and Procedures and other requirements applicable to Promotional Functions and/or Product Related Functions;

 d. the personal obligation of each individual involved in Promotional Functions and/or Product Related Functions to comply
with all applicable Federal health care program and FDA requirements and all other applicable legal requirements; 
 e. the
legal sanctions for violations of the applicable Federal health care program and FDA requirements; and 
  

 17 

 f. examples of proper and improper practices related to Promotional Functions and/or
Product Related Functions. 
 New Relevant Covered Persons shall receive the applicable training within 30 days after the
beginning of their employment or becoming Relevant Covered Persons, or within 150 days after the Effective Date, whichever is later. 

After receiving the initial Specific Training described in this Section, each Relevant Covered Person shall receive at least three hours
of the applicable Specific Training in each subsequent Reporting Period. 
 3. Board of Directors Member Training.
Within 150 days after the Effective Date, Allergan shall provide at least one hour of training to each member of the Board of Directors, in addition to the General Training. This training shall address the responsibilities of Board of Director
members and corporate governance. 
 New members of the Board of Directors shall receive the Board of Directors member training
described above within 30 days after becoming a member or within 150 days after the Effective Date, whichever is later. 
 4.
Certification. Each individual who is required to complete training shall certify, in writing or electronically, that he or she has received the required training. The certification shall specify the type of training received and the date
received. The Chief Compliance Officer (or designee) shall retain the certifications, along with all course materials. These shall be made available to OIG, upon request. 

5. Qualifications of Trainer. Persons providing the training shall be knowledgeable about the subject area of the training,
including applicable Federal health care program and FDA requirements. The training and education required under this Section III.C may be provided by supervisory employees, knowledgeable staff, Allergan trainers, and/or outside consultant trainers
selected by Allergan. 
 6. Update of Training. Allergan shall review the training annually, and, where appropriate,
update the training to reflect changes in Federal health care program requirements or FDA requirements, any issues discovered during any internal audits or any IRO Review, and any other relevant information. 

 

 18 

 7. Computer-based Training. Allergan may provide the training required under this
CIA through appropriate computer-based training approaches. If Allergan chooses to provide computer-based training, it shall make available appropriately qualified and knowledgeable staff or trainers to answer questions or provide additional
information to the Covered Persons receiving such training. 
 D. Review Procedures. 

1. General Description. 

a. Engagement of Independent Review Organization. Within 120 days after the Effective Date, Allergan shall engage an entity (or
entities), such as an accounting, auditing, or consulting firm (hereinafter “Independent Review Organization” or “IRO”), to perform reviews required by this CIA to assist Allergan in assessing and evaluating its Promotional
Functions and its Product Related Functions. The applicable requirements relating to the IRO are outlined in Appendix A to this CIA, which is incorporated by reference. 

Each IRO engaged by Allergan shall have expertise in applicable Federal health care program and FDA requirements as may be appropriate to
the Review for which the IRO is retained. Each IRO shall assess, along with Allergan, whether it can perform the engagement in a professionally independent and objective fashion, as appropriate to the nature of the review, taking into account any
other business relationships or other engagements that may exist. 
 The IRO(s) shall conduct two types of reviews that assess
Allergan’s systems, processes, policies, procedures, and practices relating to Promotional Functions and to Product Related Functions (collectively, “IRO Reviews”). 

b. Frequency and Brief Description of Reviews. As set forth more fully in Appendix B, the IRO Reviews shall consist of two
components: a Systems Review and a Transactions Review. The Systems Review shall assess Allergan’s systems, processes, policies, 

 

 19 

 
and procedures relating to Promotional Functions and Product Related Functions. If there are no material changes in Allergan’s relevant systems, processes, policies, and procedures, the IRO
Systems Review shall be performed for the periods covering the first and fourth Reporting Periods. If Allergan materially changes its relevant systems, processes, policies, and procedures, the IRO shall perform a Systems Review for the Reporting
Period in which such changes were made in addition to conducting the Systems Review for the first and fourth Reporting Periods, as set forth more fully in Appendix B. 

The Promotional and Product Services Transactions Review shall be performed annually and shall cover each of the five Reporting Periods.
The IRO(s) shall perform all components of each annual Transaction Review. As set forth more fully in Appendix B, the Transactions Review shall include several components. 

In addition, each Transactions Review shall also include a review of up to three additional areas or practices of Allergan identified by
the OIG in its discretion (hereafter “Additional Items”). For purposes of identifying the Additional Items to be included in the Transactions Review for a particular Reporting Period, the OIG will consult with Allergan and may consider
internal audit work conducted by Allergan, Allergan’s Government Reimbursed Product portfolio, the nature and scope of Allergan’s promotional practices and arrangements with HCPs and HCIs, and other information known to it. 

As set forth more fully in Appendix B, Allergan may propose to the OIG that its internal audit(s) be partially substituted for one or
more of the Additional Items that would otherwise be reviewed by the IRO as part of the Transactions Review. The OIG retains sole discretion over whether, and in what manner, to allow Allergan’s internal audit work to be substituted for a
portion of the Additional Items review conducted by the IRO. 
  

 20 

 The OIG shall notify Allergan of the nature and scope of the IRO review for each of the
Additional Items not later than 150 days prior to the end of each Reporting Period. Prior to undertaking the review of the Additional Items, the IRO and/or Allergan shall submit an audit work plan to the OIG for approval and the IRO shall conduct
the review of the Additional Items based on a work plan approved by the OIG. 
 c. Retention of Records. The IRO and
Allergan shall retain and make available to OIG, upon request, all work papers, supporting documentation, correspondence, and draft reports (those exchanged between the IRO and Allergan) related to the reviews. 

2. IRO Review Reports. The IRO(s) shall prepare a report (or reports) based upon each Review performed (IRO Review Report). The
information and content to be included in the IRO Review Report is described in Appendix B, which is incorporated by reference. 

3. Validation Review. In the event OIG has reason to believe that: (a) any IRO Review fails to conform to the requirements
of this CIA; or (b) the IRO’s findings or Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the applicable IRO Review complied with the requirements of the CIA and/or the findings
or Review results are inaccurate (Validation Review). Allergan shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Allergan’s final Annual
Report shall be initiated no later than one year after Allergan’s final submission (as described in Section II) is received by OIG. 

Prior to initiating a Validation Review, OIG shall notify Allergan of its intent to do so and provide a written explanation of why OIG
believes such a review is necessary. To resolve any concerns raised by OIG, Allergan may request a meeting with OIG to: (a) discuss the results of any Review submissions or findings; (b) present any additional information to clarify the
results of the applicable Review or to correct the inaccuracy of the Review; and/or (c) propose alternatives to the proposed Validation Review. Allergan agrees to provide any additional information as may be requested by OIG under this Section
III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Review issues with Allergan prior to conducting a Validation Review. 

 

 21 

 
However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG. 

4. Independence and Objectivity Certification. The IRO shall include in its report(s) to Allergan a certification or sworn
affidavit that it has evaluated its professional independence and objectivity, as appropriate to the nature of the engagement, with regard to the applicable Review and that it has concluded that it is, in fact, independent and objective. 

E.      Disclosure Program. Allergan currently has a disclosure program that Allergan
represents is designed to facilitate communications relating to compliance with Federal health care program and FDA requirements and Allergan’s policies (the “Disclosure Program”). During the term of the CIA, Allergan shall maintain a
Disclosure Program that includes a mechanism (a toll-free compliance telephone line and/or on-line electronic reporting) to enable individuals to disclose, to the Chief Compliance Officer or some other person who is not in the disclosing
individual’s chain of command, any identified issues or questions associated with Allergan’s policies, conduct, practices, or procedures with respect to a Federal health care program or FDA requirement believed by the individual to be a
potential violation of criminal, civil, or administrative law. Allergan shall continue to appropriately publicize the existence of the disclosure mechanism (e.g., via periodic e-mails to employees or by posting the information in prominent
common areas). 
 The Disclosure Program shall emphasize a nonretaliation policy, and shall include a reporting mechanism for
anonymous communications for which appropriate confidentiality shall be maintained. Upon receipt of a disclosure, the Chief Compliance Officer (or designee) shall gather all relevant information from the disclosing individual. The Chief Compliance
Officer (or designee) shall make a preliminary, good faith inquiry into the allegations set forth in every disclosure to ensure that he or she has obtained all of the information necessary to determine whether a further review should be conducted.
For any disclosure that is sufficiently specific so that it reasonably: 1) permits a determination of the appropriateness of the alleged improper practice; and 2) provides an opportunity for taking corrective action, Allergan shall conduct an
internal review of the allegations set forth in the disclosure and ensure that proper follow-up is conducted. 
 The Chief
Compliance Officer (or designee) shall maintain a disclosure log, which shall include a record and summary of each disclosure received (whether anonymous or 

 

 22 

 
not), the status of the respective internal reviews, and any corrective action taken in response to the internal reviews. The disclosure log shall be made available to OIG upon request.

 F. Ineligible Persons. 

1. Definitions. For purposes of this CIA: 

a. an “Ineligible Person” shall include an individual or entity who: 

i. is currently excluded, debarred, suspended, or otherwise ineligible to participate in the Federal health care programs or in Federal
procurement or nonprocurement programs; or 
 ii. has been convicted of a criminal offense that falls within the scope of 42
U.S.C. § 1320a-7(a), but has not yet been excluded, debarred, suspended, or otherwise declared ineligible. 
 b.
“Exclusion Lists” include: 
 i. the HHS/OIG List of Excluded Individuals/Entities (available through the Internet at
http://www.oig.hhs.gov); and 
 ii. the General Services Administration’s List of Parties Excluded from Federal
Programs (available through the Internet at http://www.epls.gov). 
 2. Screening Requirements. Allergan shall
ensure that all prospective and current Covered Persons are not Ineligible Persons, by implementing the following screening requirements. 

a. as part of the hiring or contracting process, Allergan shall require that all prospective and current Covered Persons disclose whether
they are Ineligible Persons and shall screen all such prospective and 
  

 23 

 
current Covered Persons against the Exclusion Lists prior to engaging their services; 

b. Allergan shall screen all Covered Persons against the Exclusion Lists within 120 days after the Effective Date and on an annual basis
thereafter. 
 c. Allergan shall implement a policy requiring all Covered Persons to disclose immediately any debarment,
exclusion, suspension, or other event that makes that person an Ineligible Person. 
 Nothing in this Section affects the
responsibility of (or liability for) Allergan to (if applicable) refrain from billing Federal health care programs for items or services furnished, ordered, or prescribed by an Ineligible Person. Allergan understands that items or services furnished
by excluded persons are not payable by Federal health care programs and that Allergan may be liable for overpayments (if applicable) and/or criminal, civil, and administrative sanctions for employing or contracting with an excluded person regardless
of whether Allergan meets the requirements of Section III.F. 
 3. Removal Requirement. If Allergan has actual notice
that a Covered Person has become an Ineligible Person, Allergan shall remove such Covered Person from responsibility for, or involvement with, Allergan’s business operations related to the Federal health care programs and shall remove such
Covered Person from any position for which the Covered Person’s compensation or the items or services furnished, ordered, or prescribed by the Covered Person are paid in whole or part, directly or indirectly, by Federal health care programs or
otherwise with Federal funds at least until such time as the Covered Person is reinstated into participation in the Federal health care programs. 

4. Pending Charges and Proposed Exclusions. If Allergan has actual notice that a Covered Person is charged with a criminal
offense that falls within the scope of 42 U.S.C. §§ 1320a-7(a), 1320a-7(b)(1)-(3), or is proposed for exclusion during the Covered Person’s employment or contract term, Allergan shall take all appropriate actions to ensure that the
responsibilities of that Covered Person have not and shall not adversely affect the quality of care rendered to any beneficiary, patient, or resident, or the accuracy of any claims submitted to any Federal health care program. 

 

 24 

 G. Notification of Government Investigation or Legal Proceedings. Within 30 days
after discovery by Allergan, Allergan shall notify OIG, in writing, of any ongoing investigation or legal proceeding conducted or brought by a U.S.-based governmental entity or its agents involving an allegation that Allergan has committed a crime
or has engaged in fraudulent activities. This notification shall include a description of the allegation, the identity of the investigating or prosecuting agency, and the status of such investigation or legal proceeding. Allergan shall also provide
written notice to OIG within 30 days after the resolution of the matter, and shall provide OIG with a description of the findings and/or results of the investigation or proceedings, if any. 

H. Reportable Events. 

1. Definition of Reportable Event. For purposes of this CIA, a “Reportable Event” means anything that involves:

 a. a matter that a reasonable person would consider a probable violation of criminal, civil, or administrative laws
applicable to any Federal health care program for which penalties or exclusion may be authorized; 
 b. a matter that a
reasonable person would consider a probable violation of criminal, civil, or administrative laws applicable to any FDA requirements relating to the promotion of Government Reimbursed Products (including an FDA Warning Letter issued to Allergan or
any Allergan Affiliate); 
 c. the employment of or contracting with a Covered Person who is an Ineligible Person as defined by
Section III.F.1.a; or 
 d. the filing of a bankruptcy petition by Allergan. 

A Reportable Event may be the result of an isolated event or a series of occurrences. 

2. Reporting of Reportable Events. If Allergan determines (after a reasonable opportunity to conduct an appropriate review or
investigation of the allegations) through any means that there is a Reportable Event, Allergan shall notify 
  

 25 

 
OIG, in writing, within 30 days after making the determination that the Reportable Event exists. 

The report to OIG shall include the following information: 

i. a complete description of the Reportable Event, including the relevant facts, persons involved, and legal and Federal health care
program and/or FDA authorities implicated; 
 ii. a description of Allergan’s actions taken to correct the Reportable
Event; and 
 iii. any further steps Allergan plans to take to address the Reportable Event and prevent it from recurring.

 iv. If the Reportable Event involves the filing of a bankruptcy petition, the report to the OIG shall include documentation
of the filing and a description of any Federal health care program authorities and/or FDA authorities implicated. 
 Allergan
shall not be required to report as a Reportable Event any matter previously disclosed under Section III.G, above. 
 I.
Notification of Communications with FDA. Within 30 days after the date of any written report, correspondence, or communication between Allergan and the FDA that materially discusses Allergan’s or a Covered Person’s actual or
potential unlawful or improper promotion of Allergan’s products (including any improper dissemination of information about off-label indications), Allergan shall provide a copy of the report, correspondence, or communication to the OIG.
Allergan shall also provide written notice to the OIG within 30 days after the resolution of any such disclosed off-label matter, and shall provide the OIG with a description of the findings and/or results of the matter, if any. 

J. Field Force Monitoring and Review Efforts. 

To the extent not already accomplished, within 120 days after the Effective Date, Allergan shall establish a comprehensive Field Force
Monitoring Program (FFMP) to 
  

 26 

 
evaluate and monitor sales representatives’ interactions with HCPs and HCIs relating to Government Reimbursed Products. The FFMP shall be a formalized process designed to directly and
indirectly observe the appropriateness of sales representatives’ interactions with HCPs relating to Government Reimbursed Products and to identify potential off-label promotional activities relating to such products. As described in more detail
below, the FFMP shall include: 1) a Speaker Monitoring Program; 2) direct field observations (Observations) of sales representatives; and 3) the monitoring and review of other records relating to sales representatives’ interactions with HCPs
and HCIs (Records Reviews). 
 Allergan represents that, prior to the Effective Date, it developed and implemented a
comprehensive system for streamlining business and compliance processes. This system is referred to as the Business Execution Automated Compliance Navigator (BEACON). BEACON is used to manage consultant arrangements with HCPs, Advisory Boards,
Speaker Programs, and provision of educational items, meals, and expenses. In addition to the data entered by individual users, BEACON interfaces with some of Allergan’s other systems, including the system through which promotional materials
are reviewed and approved and the system through which expenses are tracked. 
 Allergan represents that in BEACON, consulting
arrangements are managed through annual operating plans (discussed further below), entry of requests for individual events, including completion of a form addressing details and the business need for the event, and review and approval of those
requests. BEACON includes controls that identifies when a proposed event or arrangement does not comply with Allergan’s policies and procedures and notifies the Corporate Compliance Department of that issue for additional review and approval.
BEACON requires that documentation of the event and any expenses incurred be uploaded to the system and verified by the responsible employee. If all requirements are met, BEACON approves payments to HCPs and tracks aggregate payments. 

As it applies to certain processes, BEACON is described further below. 

1.      Speaker Program Activities. With regard to speaker programs relating to Government
Reimbursed Products, Allergan shall maintain processes to require all speakers to complete training and enter written agreements that describe the scope of work to be performed, the speaker fees to be paid, and compliance obligations for the
speakers (including requirements that the speaker may only use Allergan approved materials and may not directly or indirectly promote the product for off-label uses). 

 

 27 

 
Allergan shall maintain a centralized electronic system (BEACON) through which all such speaker programs are administered. BEACON shall establish controls regarding eligibility and qualifications
of speakers and venues for the programs and require that speakers are paid according to a centrally managed rate structure determined based on a fair-market value analysis conducted by Allergan. Allergan shall continue to maintain a comprehensive
list of speaker program attendees through BEACON. In addition, through BEACON, Allergan shall track and review the aggregate amount (including speaker fees, travel, and other expenses) paid to each speaker in connection with speaker programs
relating to Government Reimbursed Products conducted during each Reporting Period. Allergan shall require, through BEACON, certified evaluations by sales representatives or other Allergan personnel regarding whether a speaker program complied with
Allergan requirements, and in the event of non-compliance, Allergan shall require the identification of the policy violation and ensure appropriate follow up activity to address the violation. 

To the extent not already accomplished, Allergan shall institute a Speaker Monitoring Program under which Allergan compliance or
management personnel or outside personnel acting on behalf of Allergan shall attend 75 speaker programs relating to Government Reimbursed Products during each Reporting Period and conduct live monitoring of the programs (Speaker Monitoring Program).
The programs subject to the Speaker Monitoring Program shall be selected both on a risk-based targeting approach and on a sampling approach. For each program reviewed, personnel conducting the Speaker Monitoring Program shall review slide materials
and other materials used as part of the speaker program, speaker statements made during the program, and Allergan representative activities during the program to assess whether the programs were conducted in a manner consistent with Allergan’s
Policies and Procedures. Allergan shall maintain the controls around speaker programs as described above, and shall conduct its Speaker Monitoring Program as described above throughout the term of the CIA. 

2.      Observations. As a component of the FFMP, Allergan compliance personnel shall conduct
observations of sales representatives to assess whether the messages delivered and materials distributed to HCPs are consistent with applicable legal requirements and with Allergan’s Policies and Procedures. These observations shall be full day
ride-alongs with sales representatives (Observations), and each Observation shall consist of directly observing all meetings between a sales representative and HCPs during the workday. The Observations shall be scheduled throughout the year,
selected by Allergan compliance personnel both on a risk-based targeting approach and on a sampling 
  

 28 

 
approach, include each therapeutic area and actively promoted product, and be conducted across the United States. At the completion of each Observation, Allergan compliance personnel shall
prepare a report which includes: 
  

	 	1)	the identity of the sales representative; 

  

	 	2)	the identity of the Allergan compliance personnel; 

  

	 	3)	the date and duration of the Observation; 

  

	 	4)	the product(s) promoted during the Observation; 

  

	 	5)	an overall assessment of compliance with Allergan policy; and 

  

	 	6)	the identification of any potential off-label promotional activity or other improper conduct by the sales representative. 

Allergan U.S. compliance personnel shall conduct at least 30 Observations during each Reporting Period. 

3.      Records Reviews. As a component of the FFMP, Allergan shall also review various types of
records to assess sales representatives’ interactions with HCPs and HCIs and to identify potential or actual compliance violations. For each Reporting Period, Allergan shall develop and implement a plan for conducting Records Reviews associated
with at least three Government Reimbursed Products and a sampling of the representatives promoting those products in every separate region. The OIG shall have the discretion to identify the three Government Reimbursed Products to be reviewed for
each Reporting Period. The OIG will select the products based on information about Allergan’s products provided by Allergan, upon request by the OIG no later than 60 days prior to the beginning of the Reporting Period, and other information
known to the OIG. If the OIG does not identify the Government Reimbursed Products to be reviewed within the first 30 days of the Reporting Period, Allergan shall select the three products to be reviewed. 

For the first Reporting Period, the Records Reviews shall include the monitoring and review of: 1) records in BEACON relating to sales
representatives’ interactions with HCPs and HCIs relating to promotional speaker program activities, meals and expenses, and advisory boards; 2) requests for medical information; 3) sales representatives’ call notes; 4) sales
representatives’ e-mails; and 5) recorded results of the Observations of sales representatives. 
  

 29 

 For the second and subsequent Reporting Periods, the Records Reviews shall include the
monitoring and review of: 1) records in BEACON relating to sales representatives’ interactions with HCPs and HCIs; 2) requests for medical information; 3) message recall studies or any other similar records in Allergan’s possession
purporting to reflect the details of sales representatives’ interactions with HCPs and HCIs; 4) sales representative call notes; 5) sales representatives’ e-mails and any electronic records; and 6) recorded results of the Observations of
sales representatives and other notes or information from the sales representatives’ managers relating to interactions between the sales representatives and HCPs and HCIs pertaining to the Government Reimbursed Product at issue. 

4.        Reporting and Follow-up.  Personnel conducting the Speaker Monitoring
Program, Observations, and Records Reviews shall have access to all relevant records and information necessary to assess potential or actual compliance violations. Results from the FFMP monitoring, including the identification of potential
violations of policies and/or legal requirements, shall be compiled and reported to the Corporate Compliance Department for review and follow-up as appropriate. In the event that a potential violation of Allergan’s Policies and Procedures or of
legal or compliance requirements, including but not limited to potential off-label promotion, is identified during any aspect of the FFMP, Allergan shall investigate the incident consistent with established Policies and Procedures for the handling
of investigations and shall take all necessary and appropriate responsive action (including disciplinary action) and corrective action, including the disclosure of Reportable Events pursuant to Section III.H above, if applicable. Any compliance
issues identified during a Speaker Monitoring Program, Observation and/or Records Review and any corrective action shall be recorded in the files of the Corporate Compliance Department. 

Allergan shall include a summary of the FFMP and the results of the FFMP as part of each Annual Report. As part of each Annual Report,
Allergan also shall provide the OIG with copies of the Observation report for any instances in which it was determined that improper promotion occurred and a description of the action(s) that Allergan took as a result of such determinations.
Allergan shall make the Observation reports for all other Observations available to the OIG upon request. 
  

 30 

 K. Monitoring of Non-Promotional Activities. 

To the extent not already accomplished, within 150 days after the Effective Date Allergan shall develop and implement a monitoring
program for the following types of activities: 1) consultant arrangements; 2) research-related activities; 3) publication activities; and 4) medical education grants. This program shall be referred to as the Non-Promotional Monitoring Program.

 1. Consultant Arrangement Activities. To the extent that Allergan engages U.S.-based HCPs for services that relate to
Promotional Functions or to Product Related Functions, other than for speaker programs or research-related functions (e.g., as a member of an advisory board or to attend consultant meetings), such HCPs shall be referred to herein as
Consultants. Allergan shall require all Consultants to enter written agreements describing the scope of work to be performed, the fees to be paid, and compliance obligations for the Consultants. Allergan shall continue to maintain a centralized
electronic system through BEACON where all such Consultant arrangements are administered. BEACON shall establish controls regarding eligibility and qualifications of Consultants and requires that Consultants are paid according to a rate structure
based on fair market value. Allergan shall maintain a comprehensive list of Consultants through BEACON. In addition, through BEACON, Allergan shall track and review the aggregate amount paid to each Consultant in connection with Consultant
arrangements relating to Government Reimbursed Products conducted during each Reporting Period. 
 To the extent not already
accomplished, within 150 days after the Effective Date, Allergan shall establish a process to develop annual operating plans that identify the business needs for, and the estimated numbers of, various Consultant engagements and activities to occur
during the following year. Such annual operating plans shall include a needs assessment (or business rationale form) to justify the retention of a Consultant prior to the retention of the Consultant. The needs assessment shall identify the business
need for the retention of the Consultant and provide specific details about the consulting arrangement (e.g., information about the numbers and qualifications of the HCPs or HCIs to be engaged, the agenda for the proposed meeting and a
description of the proposed work to be done and type of work product to be generated). Any deviations from the Consultant operating plans shall be documented in the needs assessment form (or business rationale form) and shall be subject to review
and approval by Allergan compliance personnel. The annual operating plans shall also identify the budgeted 
  

 31 

 
amounts to be spent on Consultant-related activities. Allergan’s compliance personnel shall be involved in the review and approval of such operating plans, including any subsequent
modification of an approved plan. The purpose of this review shall be to ensure that Consultant arrangements and related events are used for legitimate purposes in accordance with applicable Allergan Policies and Procedures. 

To the extent not already accomplished, within 150 days after the Effective Date, Allergan shall amend its policies and procedures in a
manner designed to ensure that each Consultant performed the work for which the Consultant was engaged and that, as applicable, Allergan received the work product generated by the Consultant. 

Within 150 days after the Effective Date, Allergan shall establish a Consultant Monitoring Program through which it shall conduct live
monitoring for each Reporting Period (Consultant Program Observations) of at least 30 Consultant arrangements with HCPs. The Consultant Program Observations shall include live monitoring of at least 10 advisory board programs and monitoring of 20
other professional services agreements with HCPs. The Consultant Monitoring Program shall review Consultant arrangements both on a risk-based targeting approach and on a sampling approach. Allergan compliance personnel conducting the Consultant
Program Observations shall review needs assessment documents, consultant contracts, and materials relating to the program or work of the Consultant (including work product resulting from any program or event), in order to assess whether the programs
and arrangements were conducted in a manner consistent with Allergan’s Policies and Procedures. Results from the Consultant Program Observations, including the identification of potential violations of policies, shall be compiled and reported
to the Corporate Compliance Department for review and follow-up, as appropriate. 
 2. Research-Related Activities. To
the extent that Allergan or any Allergan Affiliate (hereafter in this Section III.K.2, collectively “Allergan”) provides funding or other support to U.S.-based HCPs or HCIs to conduct Phase IV post-marketing studies or IITs, such HCPs and
HCIs shall be referred to collectively as “Researchers”. Allergan shall require all Researchers to enter written agreements describing the scope of the research or other work to be performed, the fees to be paid, and compliance obligations
for the Researchers. Researchers shall be paid based on a fair-market value analysis conducted by Allergan. This fair-market value analysis shall be incorporated into guidelines that are used in the review, approval, and funding of Researchers’
activities. 
  

 32 

 
Documentation of such review, approval, and funding activities shall be maintained by Allergan Medical Affairs. 

To the extent not already accomplished, within 150 days after the Effective Date, Allergan shall establish an annual budgeting plan for
Researchers that identifies the business or scientific need for, and the estimated numbers of, the various Researcher engagements and activities to occur during the year. Allergan Medical Affairs personnel, in consultation with compliance personnel,
shall be involved in the review and approval of such budgeting plans, including any subsequent modification of an approved plan. The purpose of this review shall be to ensure that Research arrangements and related events are used for legitimate
purposes in accordance with Allergan Policies and Procedures. 
 To the extent not already accomplished, within 150 days after
the Effective Date, Allergan shall establish a process to ensure that each Researcher has submitted a needs assessment to justify the retention of the Researcher prior to the provision of funding or other support to the Researcher. The needs
assessment shall identify the business or scientific need for the information to be provided by the Researcher and provide specific details about the research arrangement (including, for example, information about the numbers and qualifications of
the HCPs or HCIs to be engaged, a description of the proposed research to be done (including the research protocol) and type of work product to be generated). 

To the extent not already accomplished, within 150 days after the Effective Date, Allergan shall amend its policies and procedures in a
manner designed to ensure that each Researcher performed the work for which the Researcher was provided funding or other support. 

Within 150 days after the Effective Date, Allergan shall establish a Researcher Monitoring Program through which it shall conduct
monitoring for each Reporting Period of at least 20 Researcher arrangements with HCPs or HCIs. The Researcher Monitoring Program shall review Researcher arrangements both on a risk-based targeting approach and on a sampling approach. Allergan
compliance personnel conducting the Researcher Monitoring Program shall review needs assessment documents, proposal and/or protocol documents, approval documents, contracts, and payments in order to assess whether the programs and arrangements were
supported by Allergan and performed by the Researchers in a manner consistent with Allergan’s Policies and Procedures. Results from the Researcher Monitoring Program, including identification of potential violations

  

 33 

 
of policies, shall be compiled and reported to the Corporate Compliance Department for review and follow-up as appropriate. 

3. Publication Activities. To the extent that Allergan engages U.S.-based HCPs or HCIs to produce articles or other publications
relating to Phase IV post-marketing studies or IITs relating to Government Reimbursed Products (collectively “Publication Activities”) such HCPs or HCIs shall be referred to as Authors. Allergan shall require all Authors to enter written
agreements describing the scope of work to be performed, the fees to be paid in connection with the Publication Activities, and compliance obligations of the Authors. Authors shall be paid based on a fair-market value analysis conducted by Allergan.
This fair-market value analysis shall be incorporated into guidelines that are used in the review, approval, and funding of Publication Activities. Documentation of such review, approval, and funding activities shall be maintained by Allergan
Medical Affairs. 
 To the extent not already accomplished, within 150 days after the Effective Date, Allergan shall establish a
process to develop annual plans that identify the business needs for and the estimated numbers of various Publication Activities (Publications Plans). The annual Publications Plan shall also identify the budgeted amounts to be spent on Publication
Activities. Allergan’s Medical Affairs personnel, in consultation with the Corporate Compliance Department personnel, shall be involved in the review and approval of such annual Publications Plans, including any modification of an approved
plan. The purpose of this review shall be to ensure that Publication Activities and related events are used for legitimate purposes in accordance with Allergan Policies and Procedures. 

To the extent not already accomplished, within 150 days after the Effective Date, Allergan shall establish a needs assessment process for
Publication Activities. This process shall ensure that a needs assessment has been completed prior to the retention of an Author for a Publication Activity. The needs assessment shall provide specific details about Publication Activities to be
performed (including a description of the proposed work to be done, type of work product to be generated, and the purpose for the work). 

Within 150 days after the Effective Date, Allergan shall establish a Publication Monitoring Program through which it shall conduct
monitoring for each Reporting Period of at least 25 U.S.-sponsored Publication Activities. The Publication Monitoring Program shall select publications for review both on a risk-based targeting approach and on a

  

 34 

 
sampling approach. Allergan compliance personnel conducting the Publication Monitoring Program shall review needs assessment documents, proposal documents, approval documents, contracts, payments
and materials relating to the Publication Activities (including work product resulting from the Activities), in order to assess whether the activities were conducted in a manner consistent with Allergan’s Policies and Procedures. Results from
the Publication Monitoring Programs, including the identification of potential violations of policies, shall be compiled and reported to the Corporate Compliance Department for review and follow-up as appropriate. 

4.        Medical Education Grant Activities.  Allergan represents that it has
established a Medical Education Department within its Medical Affairs Department as the exclusive mechanism through which requestors may seek or be awarded grants for independent medical education activities. 

Allergan represents that its sales and marketing departments have no involvement in, or influence over, the review and approval of
medical education grants. Grant requests shall be submitted through an on-line process and requests are processed in accordance with standardized criteria developed by the Medical Education Department. Allergan shall continue the medical education
grant process described above (or an equivalent process) throughout the term of the CIA, and shall notify the OIG in writing at least 60 days prior to the implementation of any new system subsequent to the Effective Date. 

To the extent not already accomplished, within 150 days after the Effective Date, Allergan shall establish a Grants Monitoring Program
through which it shall conduct monitoring for each Reporting Period of at least 30 medical education grants. The Grants Monitoring Program shall select grants for review both on a risk-based targeting approach and on a sampling approach. Allergan
compliance personnel conducting the Grants Monitoring Program shall review proposal documents (including grant requests), approval documents, contracts, payments, and materials relating to the Medical Education Department’s review of the
requests, and documents and materials relating to the grants and any events or activities funded through the grants in order to assess whether the activities are conducted in a manner consistent with Allergan’s Policies and Procedures. Results
from the Grant Monitoring Programs, including the identification of potential violations of policies, shall be compiled and reported to the Corporate Compliance Department for review and follow-up as appropriate. 

 

 35 

 5. Follow Up Reviews and Reporting. In the event that a potential violation of
Allergan’s Policies and Procedures or of legal or compliance requirements, including but not limited to potential off-label promotion, is identified during any aspect of the Non-Promotional Monitoring Program, Allergan shall investigate the
incident consistent with established Policies and Procedures for the handling of investigations and shall take all necessary and appropriate responsive action (including disciplinary action) and corrective action, including the disclosure of
Reportable Events pursuant to Section III.H above, if applicable. Any compliance issues identified during any Non-Promotional Monitoring Program referenced above, and any corrective action, shall be recorded in the files of the Corporate Compliance
Department. 
 Allergan shall include a summary of the Non-Promotional Monitoring Program and the results of the Non-Promotional
Monitoring Program as part of each Annual Report. As part of each Annual Report, Allergan also shall provide the OIG with descriptions of any instances identified through the Non-Promotional Monitoring Program in which it was determined that
improper promotion of Government Reimbursed Products occurred or the activities violated Allergan’s requirements or Policies and Procedures, and a description of the action(s) that Allergan took as a result of such determinations. Allergan
shall make the documents relating to the Non-Promotional Monitoring Program available to the OIG upon request. 
 L. Notice
to Health Care Providers and Entities. Within 90 days after the Effective Date, Allergan shall send, by first class mail, postage prepaid and return receipt requested, a notice containing the language set forth below to all HCPs and HCIs that
Allergan currently details. This notice shall be dated and shall be signed by Allergan’s President. The body of the letter shall state the following: 

As you may be aware, Allergan recently entered into a global civil, criminal and administrative settlement with the United States and
individual states in connection with the promotion and use of one of its products. This letter provides you with additional information about the settlement, explains Allergan’s commitments going forward, and provides you with access to
information about those commitments. 
 In general terms, the Government alleged that Allergan unlawfully promoted the drug Botox
for certain uses not approved by the Food & Drug Administration (FDA). To resolve these matters, Allergan pled guilty to a misdemeanor criminal 

 

 36 

 
violation of the Federal Food, Drug & Cosmetic Act (FDCA), settled certain civil claims, and agreed to pay $600 million to the Federal Government and State Medicaid programs. More
information about this settlement may be found at the following: [Allergan shall include a link to the USAO, and Allergan websites in the letter.] 

As part of the federal settlement, Allergan also entered into a five-year corporate integrity agreement with the Office of Inspector
General of the U.S. Department of Health and Human Services. The corporate integrity agreement is available at http://oig.hhs.gov/fraud/cia/index.html. Under this agreement, Allergan agreed to undertake certain obligations designed to promote
compliance with Federal health care program and FDA requirements. We also agreed to notify healthcare providers about the settlement and inform them that they can report any questionable practices by Allergan’s representatives to
Allergan’s Corporate Compliance Department or the FDA. 
 Please call or email Allergan at 1-800-TBD or [Allergan
shall insert website address in the letter] if you have questions about the settlement referenced above or to report any instances in which you believe that a Allergan representative inappropriately promoted a product or engaged in other
questionable conduct. Alternatively, you may report any such instances to the FDA’s Division of Drug Marketing, Advertising, and Communications at 301-796-1200. You should direct medical questions or concerns about the products to [insert
name and telephone number for contact line]. 
 The Chief Compliance Officer (or a designee) shall maintain a log of all
calls and messages received in response to the notice. The log shall include a record and summary of each call and message received (whether anonymous or not), the status of the call or message, and any corrective action taken in response to the
call or message. The disclosure log shall be made available to OIG upon request. As part of the Implementation Report and each Annual Report, Allergan shall provide to the OIG a summary of the calls and messages received. 

 

 37 

 M. Reporting of Physician Payments. 

1.        Reporting of Payment Information. 

(i)        Phase I Reporting: On or before April 30, 2011, Allergan shall post in a
prominent position on its website an easily accessible and readily searchable listing of all U.S.-based physicians and Related Entities (as defined below) who or which received Phase I Payments (as defined below) directly or indirectly from Allergan
during the last two quarters of 2010 and the aggregate value of such Phase I Payments. 
 On or before August 31, 2011,
Allergan shall also post on its website a listing of updated information about all Phase I Payments provided during the first two quarters of 2011. Each Phase I report shall be easily accessible and readily searchable. 

(ii)        Phase II Reporting: On or before November 30, 2011, Allergan shall post in a
prominent position on its website an easily accessible and readily searchable listing of all U.S.-based physicians and Related Entities (as defined below) who or which received Phase II Payments (as defined below) directly or indirectly from
Allergan during the third quarter of 2011 and the aggregate value of such Phase II Payments. After the November 30, 2011 posting, 60 days after the end of each subsequent calendar quarter, Allergan shall also post on its website a listing of
updated information about all Phase II payments provided during the preceding quarter(s) in each calendar year. 
 In addition,
beginning on February 29, 2012, and 60 days after the end of each subsequent calendar year, Allergan shall post on its website a report of the cumulative value of the Phase II Payments provided to all U.S.-based physicians and Related Entities
directly or indirectly from Allergan during the prior applicable calendar year. Each quarterly and annual Phase II report shall be easily accessible and readily searchable. The commencement of Phase II reporting will terminate the obligations of
Phase I reporting. 
 2.        Definitions and Miscellaneous Provisions 

(i)        Each listing made pursuant to this Section III.M shall include a complete list of all
individual physicians and Related Entities to whom or to which Allergan directly or indirectly made Payments in the preceding quarter or year (as applicable). Each listing shall be arranged alphabetically according to the physicians’ last name
or the name of the Related Entity. The Payment amounts in the lists shall be reported in 
  

 38 

 
$10,000 increments (e.g., $0 - $10,000; $10,001 - $20,000; etc.) For each physician, the applicable listing shall include the following information: i) physician’s full name; ii) name of any
Related Entities (if applicable); iii) city and state that the physician or Related Entity has provided to Allergan for contact purposes; and (iv) the aggregate value of the payment(s) in the preceding six-month period or year (as applicable).
If payments for multiple physicians have been made to one Related Entity, the aggregate value of all payments to the Related Entity will be the reported amount. 

Allergan shall continue to make each annual listing and the most recent quarterly listing of Payments available on its website at least
throughout the term of this CIA. Allergan shall retain and make available to OIG, upon request, all supporting documentation, correspondence, and records related to all applicable Payments and to the annual and/or quarterly listings of Payments.
Nothing in this Section III.M affects the responsibility of Allergan to comply with (or liability for noncompliance with) all applicable Federal health care program requirements and state laws as they relate to all applicable Payments made to
physicians or Related Entities. 
 (ii)      For purposes of this Section III.M, the term
“Phase I Payments” is defined to include all payments or transfers of value (whether in cash or in kind) made by Allergan to physicians and/or to Related Entities related to meals, speaker programs, or advisory boards conducted by Sales,
Marketing, or Medical Affairs. 
 (iii)    For purposes of Section III.M.1, “Phase II Payments” is
defined to include all “payments or transfers of value” as that term is defined in §1128G(e)(10) under Section 6002 of the Patient Protection and Affordable Care Act (Public Law 111-148) (Affordable Care Act) and any regulations
promulgated thereunder. The term Payments include, by way of example, the types of payments or transfers of value enumerated in §1128G(a)(1)(A)(vi) of the Affordable Care Act. The term includes all payments or transfers of value made to Related
Entities on behalf of, at the request of, for the benefit or use of, or under the name of a physician for whom Allergan world otherwise report a Payment if made directly to the physician. The term Payments also includes any payments or transfers of
value made, directly by Allergan or by a vendor retained by Allergan to a physician or Related Entity in connection with, or under the auspices of, a co-promotion arrangement. 

(iv)    The term “Payments” does not include transfers of value or other items that are not included or are
excluded from the definition of “payment” as set forth in § 
  

 39 

 
1128G(e)(10) under Section 6002 of the Affordable Care Act and any regulations promulgated thereunder. 

(v)      For purposes of this Section III.M, the term “Related Entity” is defined to be any
entity by or in which any physician receiving Payments is employed, has tenure, or has an ownership interest. 
 N. Other
Transparency/Disclosure Initiatives. 
 Within 120 days after the Effective Date of this CIA, and thereafter on a bi-annual
basis, Allergan shall post on its company website the following information with respect to both medical education grants and charitable contributions to U.S.-based HCIs: 1) the recipient organization’s name: 2) a brief description of the
program for which the grant or charitable contribution was requested; and 3) the amount of the grant or charitable contribution. Allergan shall continue to post (and provide updates to) the above-described information about medical education grants
and charitable contributions to U.S.-based HCIs throughout the term of this CIA. Allergan shall notify the OIG in writing at least 60 days prior to any change in the substance of its policies regarding the funding of medical education grants and
charitable contributions to U.S.-based HCIs or posting of the above-referenced information relating to such funding. 
 Allergan
represents that it requires all U.S.-based Consultants to fully comply with all applicable disclosure obligations relating to their relationship with Allergan that may be externally imposed on the Consultants based on their affiliation with
formulary or Pharmacy & Therapeutics committees or committees associated with the development of treatment protocols or standards. Allergan shall continue this requirement throughout the term of this CIA. Within 120 days after the Effective
Date, Allergan shall amend its policies relating to Consultants to explicitly state Allergan’s requirement about full disclosure by Consultants consistent with the requirements of any HCI, medical committee, or other medical or scientific
organization with which the Consultants are affiliated. In addition, for any amendment to its contracts with Consultants and in any new contracts with Consultants entered into after 120 days following the Effective Date, Allergan shall include an
explicit requirement that the Consultants fully comply with applicable disclosure requirements and disclose their relationship with Allergan as required pursuant to their affiliation with any HCI, medical committee, or other medical or scientific
organization. 
  

 40 

 Allergan represents that it expects all Authors of biomedical manuscripts to fully comply
with the International Committee of Medical Journal Editors (ICMJE) criteria regarding authorship and disclosure of their relationship with Allergan and to disclose any potential conflicts of interest, including any financial or personal
relationships that might be perceived to bias their work. Within 120 days after the Effective Date, Allergan shall amend its policies relating to Authors to explicitly state Allergan’s requirement about full disclosure by Authors consistent
with the requirements of any HCI, medical committee or other medical or scientific organization with which the Authors are affiliated. In addition, for any amendments to its contracts with Authors and in any new contracts with Authors entered into
after 120 days following the Effective Date, Allergan shall include an explicit requirement that Authors disclose in their manuscripts, journal submissions, and elsewhere as appropriate or required, any potential conflicts of interest, including
their financial or personal relationship with Allergan, the names of any individuals who have provided editorial support for any manuscript or other publication, and all funding sources for the study or publication. 

Allergan represents that for all applicable clinical trials (as defined by 42 U.S.C. §282(j)) where Allergan is a sponsor, it
registers and reports the results on the National Institutes of Health (NIH) sponsored website (www.clinicaltrials.gov) or requires that another responsible party (as defined by 42 U.S.C. § 282(j)) register and report the results on the
NIH website. Allergan shall continue to comply with Federal health care program requirements, FDA requirements, or other applicable requirements relating to the reporting of clinical study information throughout the term of this CIA. In addition, if
there is a change in Federal health care program requirements, FDA requirements, or other applicable requirements relating to the reporting of clinical study information, Allergan shall fully comply with such requirements. 

Allergan represents that it posts information on its company website about postmarketing commitments (PMCs). The Allergan website
(www.allergan.com) provides access to general information about the PMC process, including study descriptions and information abut the nature and status of FDA PMCs. Allergan shall continue to post the above-described information about PMCs
on its website throughout the term of this CIA. 
  

 41 

	IV.	CHANGES TO BUSINESS UNITS OR LOCATIONS

 A. Change or Closure of Unit or Location. In the event that, after the Effective Date, Allergan
changes locations or closes a business unit or location related to Promotional Functions or Product Related Functions, Allergan shall notify OIG of this fact as soon as possible, but no later than within 30 days after the date of change or closure
of the location. 
 B. Purchase or Establishment of New Unit or Location. In the event that, after the Effective Date,
Allergan purchases or establishes a new business unit or location related to Promotional Functions or Product Related Functions, Allergan shall notify OIG no later than five days after the date that the purchase or establishment is publicly
disclosed by Allergan. This notification shall include the address of the new business unit or location, phone number, fax number, Federal health care program provider or supplier number (if applicable), and the name and address of the contractor
that issued each number (if applicable). Each new business unit or location and all Covered Persons at each new business unit or location shall be subject to the applicable requirements of this CIA. 

C. Sale of Unit or Location. In the event that, after the Effective Date, Allergan proposes to sell any or all of its business
units or locations related to Promotional Functions or Product Related Functions that are subject to this CIA, Allergan shall notify OIG of the proposed sale no later than 5 days after the date the sale is publicly disclosed by Allergan. This
notification shall include a description of the business unit or location to be sold, a brief description of the terms of the sale, and the name and contact information of the prospective purchaser. This CIA shall be binding on the purchaser of such
business unit or location, unless otherwise determined and agreed to in writing by the OIG. 
  

	V.	IMPLEMENTATION AND ANNUAL REPORTS 

A. Implementation Report. Within 180 days after the Effective Date, Allergan shall submit a written report to OIG summarizing the
status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include: 
  

 42 

 1. the name, address, phone number, and position description of the Chief Compliance
Officer required by Section III.A.1, and a summary of other noncompliance job responsibilities the Chief Compliance Officer may have; 

2. the names and positions of the members of the U.S. Compliance Committee required by Section III.A.2; 

3. the names of the members of the full Board of Directors and any Committee of the Board with responsibility for compliance as
referenced in Section III.A.3; 
 4. the names and positions of the Certifying Employees required by Section III.A.4;

 5. a copy of Allergan’s Code of Conduct required by Section III.B.1; 

6. the number of Covered Persons required to complete the Code of Conduct certification required by Section III.B.1, the percentage of
Covered Persons who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be available to OIG, upon request); 

7. a) a copy of the letter (including all attachments) required by Section II.C.6 and III.B.2 sent to each party employing Third Party
Personnel; b) a list of all such existing co-promotion and other applicable agreements; and c) a description of the entities’ response to Allergan’s letter; 

8. a summary of all Policies and Procedures required by Section III.B.3 (a copy of such Policies and Procedures shall be made available
to OIG upon request); 
 9. the following information regarding each type of training required by Section III.C: 

a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training
sessions; and 
  

 43 

 b. the number of Covered Persons required to be trained, percentage of Covered Persons
actually trained, and an explanation of any exceptions. 
 A copy of all training materials and the documentation supporting this information
shall be available to OIG, upon request; 
 10. the following information regarding the IRO(s): (a) identity, address, and
phone number; (b) a copy of the engagement letter; and (c) a summary and description of any and all current and prior engagements and agreements between Allergan and the IRO; 

11. a certification from the IRO regarding its professional independence and objectivity with respect to Allergan; 

12. a description of the Disclosure Program required by Section III.E; 

13. a description of the process by which Allergan fulfills the requirements of Section III.F regarding Ineligible Persons; 

14. the name, title, and responsibilities of any person who is determined to be an Ineligible Person under Section III.F; the actions
taken in response to the screening and removal obligations set forth in Section III.F; 
 15. a certification by the Chief
Compliance Officer that the notice required by Section III.L was mailed to each HCP and HCI, the number of HCPs and HCIs that received a copy of the notice, a sample copy of the notice required by Section III.L, and a summary of the calls or
messages received in response to the notice; 
 16. a list of all of Allergan’s U.S. locations (including locations and
mailing addresses); the corresponding name under which each location is doing business; and the corresponding phone numbers and fax numbers; 

17. a description of Allergan’s corporate structure, including identification of any parent and sister companies, subsidiaries, and
their respective lines of business; and 
  

 44 

 18. the certifications required by Section V.C.2. 

B. Annual Reports. Allergan shall submit to OIG annually a report with respect to the status of, and findings regarding,
Allergan’s compliance activities for each of the five Reporting Periods (Annual Report). 
 Each Annual Report shall include, at a minimum:

 1. an explanation of any change in the identity, position description, or other noncompliance job responsibilities of the
Chief Compliance Officer and any change in the membership of the U.S. Compliance Committee, the Board, or the group of Certifying Employees described in Sections III.A.2-4; 

2. a complete copy of all reports prepared pursuant to Section III.A.3, 

3. Allergan’s response and action plans(s) related to any issues raised by the reports prepared pursuant to Section III.A.3;

 4. a copy of the resolution by the Board required by Section III.A.3; 

5. a summary of any significant changes or amendments to the Policies and Procedures required by Section III.B and the reasons for such
changes (e.g., change in applicable requirements); 
 6. the number of Covered Persons required to complete the Code of
Conduct certification required by Section III.B.1, the percentage of Covered Persons who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be available to OIG, upon request);

 7. a) a copy of the letter (including all attachments) required by Section II.C.6 and III.B.2 sent to each party employing
Third Party Personnel; b) a list of all such existing co-promotion and other applicable agreements; and c) a description of the entities’ response to Allergan’s letter; 

8. the following information regarding each type of training required by Section III.C: 

 

 45 

 a. a description of the initial and annual training, including a summary of the topics
covered, the length of sessions, and a schedule of training sessions; and 
 b. the number of individuals required to complete
the initial and annual training, the percentage of individuals who actually completed the initial and annual training, and an explanation of any exceptions. 

A copy of all training materials and the documentation supporting this information shall be available to OIG, upon request. 

9. a complete copy of all reports prepared pursuant to Section III.D; 

10. Allergan’s response and corrective action plan(s) related to any issues raised by the reports prepared pursuant to Section
III.D; 
 11. a summary and description of any and all current and prior engagements and agreements between Allergan and the
IRO, if different from what was submitted as part of the Implementation Report; 
 12. a certification from the IRO regarding
its professional independence and objectivity with respect to Allergan; 
 13. a summary of the disclosures in the disclosure
log required by Section III.E that relate to the Government Reimbursed Products or to Federal health care programs; 
 14. any
changes to the process by which Allergan fulfills the requirements of Section III.F regarding Ineligible Persons; 
 15. the
name, title, and responsibilities of any person who is determined to be an Ineligible Person under Section III.F; the actions taken by Allergan in response to the screening and removal obligations set forth in Section III.F; 

16. a summary describing any ongoing investigation or legal proceeding required to have been reported pursuant to Section III.G. The
summary shall include a 
  

 46 

 
description of the allegation, the identity of the investigating or prosecuting agency, and the status of such investigation or legal proceeding; 

17. a summary of Reportable Events (as defined in Section III.H) identified during the Reporting Period and the status of any corrective
and preventative action relating to all such Reportable Events; 
 18. a summary describing any written communication with the
FDA required to have been reported pursuant to Section III.I. This summary shall include a description of the matter and the status of the matter; 

19. a summary of the FFMP and the results of the FFMP required by Section III.J, including copies of the Observation report for any
instances in which it was determined that improper promotion occurred and a description of the action(s) that Allergan took as a result of such determinations; 

20. a summary of the Non-Promotional Monitoring Program and the results of the program described in Section III.K, including detailed
description of any identified instances in which it was determined that the activities violated Allergan’s policies or that improper promotion of Government Reimbursed Products occurred and a description of the action(s) Allergan took as a
result of such determinations; 
 21. a summary of the calls and messages received in response to the notice required by
Section III.L and the disposition of those calls and messages; 
 22. a certification from the Chief Compliance Officer that,
if required under Section III.M and to the best of his/her knowledge, information regarding Payments has been posted on Allergan’s website as required by Section III.M; 

23. a description of all changes to the most recently provided list of Allergan’s locations (including addresses) as required by
Section V.A.16; the corresponding name under which each location is doing business; and the corresponding phone numbers and fax numbers; and 

24. a description of any additional, updated, supplemental or changed information submitted to any Compendia in accordance with Section
III.B.3.r; and a description of all arrangements, processing fees, and other payments or financial support 
  

 47 

 
(if any) with or made to any Compendia evaluated during the annual review described in Section III.B.3.t; and 

25. the certifications required by Section V.C. 

The first Annual Report shall be received by OIG no later than 90 days after the end of the first Reporting Period. Subsequent Annual
Reports shall be received by OIG no later than the anniversary date of the due date of the first Annual Report. 
 C.
Certifications. The following certifications shall be included in the Implementation Report and Annual Reports: 
 1.
Certifying Employees: In each Annual Report, Allergan shall include the certifications of Certifying Employees as required by Section III.A.4; 

2. Chief Compliance Officer: In the Implementation Report and Annual Reports, Allergan shall include the following individual
certification by the Compliance Officer: 
 a. he or she has reviewed the Report and has made reasonable inquiry regarding its
content and believes that the information in the Report is accurate and truthful; 
 b. to the best of his or her knowledge,
except as otherwise described in the applicable report, Allergan is in compliance with the Federal health care program and FDA requirements and the obligations of the CIA; 

c. he or she has verified with appropriate personnel that Allergan’s: 1) Policies and Procedures as referenced in Section III.B.3
above; 2) templates for standardized contracts and other similar documents; 3) the training materials used for purposes of Section III.C; and 4) Allergan’s reimbursement support services policies, procedures, and practices (as referenced in
Section III.B.3.f) all have been reviewed by competent legal counsel and/or legal personnel working at their direction and have been found to be in compliance with all applicable Federal health care program and FDA requirements. If the applicable
legal requirements have not changed, after the initial review of the documents listed above, only material changes to the documents must be reviewed by competent legal counsel and/or legal personnel working at their direction.

  

 48 

 
The certification shall include a description of the document(s) reviewed and approximately when the review was completed. The documentation supporting this certification shall be available to
OIG, upon request; 
 d. he or she has verified with appropriate personnel that, except as otherwise described in the
applicable report, Allergan’s promotional materials containing claims or information about Government Reimbursed Products and other materials and information intended to be disseminated outside Allergan have been reviewed by competent
regulatory, medical, and/or legal personnel in accordance with applicable Policies and Procedures to ensure that legal, medical, and regulatory concerns are properly addressed and are elevated when appropriate, and that the materials and information
when finally approved are in compliance with all applicable Federal health care program and FDA requirements. If the applicable legal requirements have not changed, after the initial review of the documents listed above, only material changes to the
documents must be reviewed by competent regulatory, medical, and/or legal personnel. The certification shall include a description of the document(s) reviewed and approximately when the review was completed. The documentation supporting this
certification shall be available to OIG, upon request; and 
 e. he or she has verified with appropriate personnel that
Allergan’s Call Plans for Government Reimbursed Products were reviewed at least once during the Reporting Period (consistent with Section III.B.3.j) and, for each product the Call Plans were found to be consistent with Allergan’s policy
objectives as referenced above in Section III.B.3.j. 
 D. Designation of Information. Allergan shall clearly identify
any portions of its submissions that it believes are trade secrets, or information that is commercial or financial and privileged or confidential, and therefore potentially exempt from disclosure under the Freedom of Information Act (FOIA), 5 U.S.C.
§ 552. Allergan shall refrain from identifying any information as exempt from disclosure if that information does not meet the criteria for exemption from disclosure under FOIA. 

 

	VI.	NOTIFICATIONS AND SUBMISSION OF REPORTS

 Unless otherwise stated in writing after the Effective Date, all notifications and reports required under
this CIA shall be submitted to the following entities: 
  

 49 

			
	OIG:	  	Administrative and Civil Remedies Branch
		  	Office of Counsel to the Inspector General
		  	Office of Inspector General
		  	U.S. Department of Health and Human Services
		  	Cohen Building, Room 5527
		  	330 Independence Avenue, S.W.
		  	Washington, DC 20201
		  	Telephone: 202.619.2078
		  	Facsimile: 202.205.0604
		
	Allergan:	  	Chief Compliance Officer
		  	Allergan, Inc.
		  	2525 Dupont Drive
		  	P.O. Box 19534
		  	Irvine, CA 92623
		  	Telephone: 714.246.4500
		  	Facsimile: 714.246.4971

 Unless otherwise specified, all
notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile
confirmation sheets do not constitute proof of receipt. Upon request by OIG, Allergan may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either
instead of or in addition to, a paper copy. 
  

	VII.	OIG INSPECTION, AUDIT, AND REVIEW RIGHTS

 In addition to any other rights OIG may have by statute, regulation, or contract, OIG or its duly authorized
representative(s) may examine or request copies of Allergan’s books, records, and other documents and supporting materials and/or conduct on-site reviews of any of Allergan’s locations for the purpose of verifying and evaluating:
(a) Allergan’s compliance with the terms of this CIA; and (b) Allergan’s compliance with the requirements of the Federal health care programs in which it participates and with all applicable FDA requirements. The documentation
described above shall be made available by Allergan to OIG or its duly authorized representative(s) at all reasonable times for inspection, audit, or reproduction. Furthermore, for purposes of this provision,

  

 50 

 
OIG or its duly authorized representative(s) may interview any of Allergan’s employees, contractors, or agents who consent to be interviewed at the individual’s place of business during
normal business hours or at such other place and time as may be mutually agreed upon between the individual and OIG. Allergan shall assist OIG or its duly authorized representative(s) in contacting and arranging interviews with such individuals upon
OIG’s request. Allergan’s employees may elect to be interviewed with or without a representative of Allergan present. 
  

	VIII.	DOCUMENT AND RECORD RETENTION 

Allergan shall maintain for inspection all documents and records relating to reimbursement from the Federal health care programs, or to
compliance with this CIA, for six years (or longer if otherwise required by law) from the Effective Date. 
  

	IX.	DISCLOSURES  

Consistent with HHS’s FOIA procedures, set forth in 45 C.F.R. Part 5, OIG shall make a reasonable effort to notify Allergan prior to
any release by OIG of information submitted by Allergan pursuant to its obligations under this CIA and identified upon submission by Allergan as trade secrets, or information that is commercial or financial and privileged or confidential, under the
FOIA rules. With respect to such releases, Allergan shall have the rights set forth at 45 C.F.R. § 5.65(d). 
  

	X.	BREACH AND DEFAULT PROVISIONS 

Allergan is expected to fully and timely comply with all of its CIA obligations. The breach and default remedies available to the OIG
under this Section X do not preempt or limit any actions that individual States may take against Allergan under applicable legal authorities or under any applicable settlement agreement or consent decree between the State and Allergan. 

A. Stipulated Penalties for Failure to Comply with Certain Obligations. As a contractual remedy, Allergan and OIG hereby agree
that failure to comply with certain obligations as set forth in this CIA may lead to the imposition of the following monetary penalties (hereinafter referred to as “Stipulated Penalties”) in accordance with the following provisions.

  

 51 

 1. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date
the obligation became due) for each day Allergan fails to establish, implement, or accomplish any of the following obligations as described in Section III: 

a. a Chief Compliance Officer; 

b. a U.S. Compliance Committee; 

c. the resolution from the Board; 

d. a written Code of Conduct; 

e. written Policies and Procedures; 

f. the training of Covered Persons and Relevant Covered Persons; 

g. a Disclosure Program; 

h. Ineligible Persons screening and removal requirements; 

i. notification of Government investigations or legal proceedings; 

j. notification of written communications with FDA as required by Section III.I; 

k. a program for FFMP as required by Section III.J; 

l. a program for Non-Promotional Monitoring Activities as required by Section III.K; 

m. notification to HCPs and HCIs as required by Section III.L; 

n. posting of any Payments as required by Section III.M; 

o. the reporting of any Reportable Event. 

2. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day 

 

 52 

 
after the date the obligation became due) for each day Allergan fails to engage an IRO as required in Section III.D and Appendices A-B. 

3. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day
Allergan fails to submit the Implementation Report or the Annual Reports to OIG in accordance with the requirements of Section V by the deadlines for submission. 

4. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day
Allergan fails to submit the annual IRO Review Report(s) in accordance with the requirements of Section III.D and Appendices A-B. 

5. A Stipulated Penalty of $1,500 for each day Allergan fails to grant access as required in Section VII. (This Stipulated Penalty shall
begin to accrue on the date Allergan fails to grant access.) 
 6. A Stipulated Penalty of $5,000 for each false certification
submitted by or on behalf of Allergan as part of its Implementation Report, Annual Report, additional documentation to a report (as requested by the OIG), or otherwise required by this CIA. 

7. A Stipulated Penalty of $1,000 for each day Allergan fails to comply fully and adequately with any obligation of this CIA. OIG shall
provide notice to Allergan, stating the specific grounds for its determination that Allergan has failed to comply fully and adequately with the CIA obligation(s) at issue and steps Allergan shall take to comply with the CIA. (This Stipulated Penalty
shall begin to accrue 10 days after Allergan receives this notice from OIG of the failure to comply.) A Stipulated Penalty as described in this Subsection shall not be demanded for any violation for which OIG has sought a Stipulated Penalty under
Subsections 1-6 of this Section. 
 B. Timely Written Requests for Extensions. Allergan may, in advance of the due date,
submit a timely written request for an extension of time to perform any act or file any notification or report required by this CIA. Notwithstanding any other provision in this Section, if OIG grants the timely written request with respect to an
act, notification, or report, Stipulated Penalties for failure to perform the act or file the notification or report shall not begin to accrue until one day after Allergan fails to meet the revised deadline set by OIG. Notwithstanding any other
provision in this Section, if OIG denies 
  

 53 

 
such a timely written request, Stipulated Penalties for failure to perform the act or file the notification or report shall not begin to accrue until three business days after Allergan receives
OIG’s written denial of such request or the original due date, whichever is later. A “timely written request” is defined as a request in writing received by OIG at least five business days prior to the date by which any act is due to
be performed or any notification or report is due to be filed. 
 C. Payment of Stipulated Penalties. 

1. Demand Letter. Upon a finding that Allergan has failed to comply with any of the obligations described in Section X.A and
after determining that Stipulated Penalties are appropriate, OIG shall notify Allergan of: (a) Allergan’s failure to comply; and (b) OIG’s exercise of its contractual right to demand payment of the Stipulated Penalties (this
notification is referred to as the “Demand Letter”). 
 2. Response to Demand Letter. Within 10 days after the
receipt of the Demand Letter, Allergan shall either: (a) cure the breach to OIG’s satisfaction and pay the applicable Stipulated Penalties; or (b) request a hearing before an HHS administrative law judge (ALJ) to dispute OIG’s
determination of noncompliance, pursuant to the agreed upon provisions set forth below in Section X.E. In the event Allergan elects to request an ALJ hearing, the Stipulated Penalties shall continue to accrue until Allergan cures, to OIG’s
satisfaction, the alleged breach in dispute. Failure to respond to the Demand Letter in one of these two manners within the allowed time period shall be considered a material breach of this CIA and shall be grounds for exclusion under Section X.D.

 3. Form of Payment. Payment of the Stipulated Penalties shall be made by electronic funds transfer to an account
specified by OIG in the Demand Letter. 
 4. Independence from Material Breach Determination. Except as set forth in
Section X.D.1.c, these provisions for payment of Stipulated Penalties shall not affect or otherwise set a standard for OIG’s decision that Allergan has materially breached this CIA, which decision shall be made at OIG’s discretion and
shall be governed by the provisions in Section X.D, below. 
 D. Exclusion for Material Breach of this CIA. 

1. Definition of Material Breach. A material breach of this CIA means: 

 

 54 

 a. a repeated or flagrant violation of the obligations under this CIA, including, but not
limited to, the obligations addressed in Section X.A; 
 b. a failure to respond to a Demand Letter concerning the payment of
Stipulated Penalties in accordance with Section X.C; or 
 c. a failure of the Board to issue a resolution in accordance with
Section III.A.3. 
 2. Notice of Material Breach and Intent to Exclude. The parties agree that a material breach of this
CIA by Allergan constitutes an independent basis for Allergan’s exclusion from participation in the Federal health care programs. Upon a determination by OIG that Allergan has materially breached this CIA and that exclusion is the appropriate
remedy, OIG shall notify Allergan of: (a) Allergan’s material breach; and (b) OIG’s intent to exercise its contractual right to impose exclusion (this notification is hereinafter referred to as the “Notice of Material Breach
and Intent to Exclude”). 
 3. Opportunity to Cure. Allergan shall have 30 days from the date of receipt of the
Notice of Material Breach and Intent to Exclude to demonstrate to OIG’s satisfaction that: 
 a. Allergan is in compliance
with the obligations of the CIA cited by OIG as being the basis for the material breach; 
 b. the alleged material breach has
been cured; or 
 c. the alleged material breach cannot be cured within the 30-day period, but that: (i) Allergan has begun
to take action to cure the material breach; (ii) Allergan is pursuing such action with due diligence; and (iii) Allergan has provided to OIG a reasonable timetable for curing the material breach. 

4. Exclusion Letter. If, at the conclusion of the 30-day period, Allergan fails to satisfy the requirements of Section X.D.3, OIG
may exclude Allergan from participation in the Federal health care programs. OIG shall notify Allergan in writing of 

 

 55 

 
its determination to exclude Allergan (this letter shall be referred to hereinafter as the “Exclusion Letter”). Subject to the Dispute Resolution provisions in Section X.E, below, the
exclusion shall go into effect 30 days after the date of Allergan’s receipt of the Exclusion Letter. The exclusion shall have national effect and shall also apply to all other Federal procurement and nonprocurement programs. Reinstatement to
program participation is not automatic. After the end of the period of exclusion, Allergan may apply for reinstatement by submitting a written request for reinstatement in accordance with the provisions at 42 C.F.R.
§§ 1001.3001-.3004. 
 E. Dispute Resolution 

1. Review Rights. Upon OIG’s delivery to Allergan of its Demand Letter or of its Exclusion Letter, and as an agreed-upon
contractual remedy for the resolution of disputes arising under this CIA, Allergan shall be afforded certain review rights comparable to the ones that are provided in 42 U.S.C. § 1320a-7(f) and 42 C.F.R. Part 1005 as if they applied to the
Stipulated Penalties or exclusion sought pursuant to this CIA. Specifically, OIG’s determination to demand payment of Stipulated Penalties or to seek exclusion shall be subject to review by an HHS ALJ and, in the event of an appeal, the HHS
Departmental Appeals Board (DAB), in a manner consistent with the provisions in 42 C.F.R. § 1005.2-1005.21. Notwithstanding the language in 42 C.F.R. § 1005.2(c), the request for a hearing involving Stipulated Penalties shall be made
within 10 days after receipt of the Demand Letter and the request for a hearing involving exclusion shall be made within 25 days after receipt of the Exclusion Letter. 

2. Stipulated Penalties Review. Notwithstanding any provision of Title 42 of the United States Code or Title 42 of the Code of
Federal Regulations, the only issues in a proceeding for Stipulated Penalties under this CIA shall be: (a) whether Allergan was in full and timely compliance with the obligations of this CIA for which OIG demands payment; and (b) the
period of noncompliance. Allergan shall have the burden of proving its full and timely compliance and the steps taken to cure the noncompliance, if any. OIG shall not have the right to appeal to the DAB an adverse ALJ decision related to Stipulated
Penalties. If the ALJ agrees with OIG with regard to a finding of a breach of this CIA and orders Allergan to pay Stipulated Penalties, such Stipulated Penalties shall become due and payable 20 days after the ALJ issues such a decision unless
Allergan requests review of the ALJ decision by the DAB. If the ALJ decision is properly appealed to the DAB and the DAB upholds the determination of OIG, the 

 

 56 

 
Stipulated Penalties shall become due and payable 20 days after the DAB issues its decision. 

3. Exclusion Review. Notwithstanding any provision of Title 42 of the United States Code or Title 42 of the Code of Federal
Regulations, the only issues in a proceeding for exclusion based on a material breach of this CIA shall be: 
 a. whether
Allergan was in material breach of this CIA; 
 b. whether such breach was continuing on the date of the Exclusion Letter; and

 c. whether the alleged material breach could not have been cured within the 30-day period, but that: (i) Allergan had
begun to take action to cure the material breach within that period; (ii) Allergan has pursued and is pursuing such action with due diligence; and (iii) Allergan provided to OIG within that period a reasonable timetable for curing the
material breach and Allergan has followed the timetable. 
 For purposes of the exclusion herein, exclusion shall take effect
only after an ALJ decision favorable to OIG, or, if the ALJ rules for Allergan, only after a DAB decision in favor of OIG. Allergan’s election of its contractual right to appeal to the DAB shall not abrogate OIG’s authority to exclude
Allergan upon the issuance of an ALJ’s decision in favor of OIG. If the ALJ sustains the determination of OIG and determines that exclusion is authorized, such exclusion shall take effect 20 days after the ALJ issues such a decision,
notwithstanding that Allergan may request review of the ALJ decision by the DAB. If the DAB finds in favor of OIG after an ALJ decision adverse to OIG, the exclusion shall take effect 20 days after the DAB decision. Allergan shall waive its right to
any notice of such an exclusion if a decision upholding the exclusion is rendered by the ALJ or DAB. If the DAB finds in favor of Allergan, Allergan shall be reinstated effective on the date of the original exclusion. 

4. Finality of Decision. The review by an ALJ or DAB provided for above shall not be considered to be an appeal right arising
under any statutes or regulations. Consequently, the parties to this CIA agree that the DAB’s decision (or the ALJ’s decision if not appealed) shall be considered final for all purposes under this CIA. 

 

 57 

	XI.	EFFECTIVE AND BINDING AGREEMENT 

Allergan and OIG agree as follows: 

A. This CIA shall be binding on the successors, assigns, and transferees of Allergan; 

B. This CIA shall become final and binding on the date the final signature is obtained on the CIA; 

C. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to
this CIA; 
 D. The undersigned Allergan signatories represent and warrant that they are authorized to execute this CIA. The
undersigned OIG signatory represents that he is signing this CIA in his official capacity and that he is authorized to execute this CIA; and 

E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA.
Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. 
  

 58 

 ON BEHALF OF ALLERGAN,
INC. 
  

							
	 /s/ Rose-Karen Swanson
	 		 	 8/30/10
	 	
				
	Rose-Karen Swanson	 		 	Date	 	
	Chief Compliance Officer	 		 		 	
	Allergan, Inc.	 		 		 	
				
	 /s/ John T. Bentivoglio
	 		 	 8/30/10
	 	
				
	John T. Bentivoglio	 		 		 	
	Skadden, Arps, Slate, Meagher & Flom LLP	 		 	Date	 	
	Counsel for Allergan, Inc.	 		 		 	
				
	 /s/ Jennifer L. Bragg
	 		 	 8/30/10
	 	
				
	Jennifer L. Bragg	 		 	Date	 	
	Skadden, Arps, Slate, Meagher & Flom LLP	 		 		 	
	Counsel for Allergan, Inc.	 		 		 	
				
	 /s/ Stephen S. Cowen
	 		 	 8/30/10
	 	
	Stephen S. Cowen	 		 	Date	 	
	King & Spalding LLP	 		 		 	
	Counsel for Allergan, Inc.	 		 		 	

  

 59 

 ON BEHALF OF THE
OFFICE OF INSPECTOR GENERAL 
 OF
THE DEPARTMENT OF HEALTH AND HUMAN SERVICES 
  

					
	     /s/ Gregory E. Demske
	 		 	     8/20/10

			
	Gregory E. Demske	 		 	DATE
	Assistant Inspector General for Legal Affairs	 	
	Office of Inspector General	 	
	U. S. Department of Health and Human Services	 	

  

 60 

 APPENDIX A 

INDEPENDENT REVIEW ORGANIZATION 

This Appendix contains the requirements relating to the Independent Review Organization (IRO) required by Section III.D of the CIA. 

 

	A.	IRO Engagement 

 Allergan
shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in
Paragraph D. Within 30 days after OIG receives written notice of the identity of the selected IRO, OIG will notify Allergan if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Allergan may continue to engage the
IRO. 
 If Allergan engages a new IRO during the term of the CIA, this IRO shall also meet the requirements of this Appendix. If
a new IRO is engaged, Allergan shall submit the information identified in Section V.A.10 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives written notice of the identity of the selected IRO, OIG will notify
Allergan if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Allergan may continue to engage the IRO. 
  

	B.	IRO Qualifications. 

 The IRO shall:

 1. assign individuals to conduct the IRO Reviews who have expertise in all applicable Federal health care program and FDA
requirements relating to Promotional Functions and to Product Related Functions. The assigned individuals shall also be knowledgeable about the general requirements of the Federal health care program(s) under which Allergan’s Government
Reimbursed Products are reimbursed; 
 2. assign individuals to design and select the samples for the Transaction Reviews who
are knowledgeable about the appropriate statistical sampling techniques; and 
 3. have sufficient staff and resources to
conduct the reviews required by the CIA on a timely basis. 
  

 1 

	C.	IRO Responsibilities. 

 The IRO shall:

 1. perform each IRO Review in accordance with the specific requirements of the CIA; 

2. follow all applicable Federal health care program and FDA requirements in making assessments in each IRO Review; 

3. if in doubt of the application of a particular Federal health care program or FDA requirement, policy, or regulation, request
clarification from the appropriate authority (e.g., CMS or FDA); 
 4. respond to all OIG inquires in a prompt,
objective, and factual manner; and 
 5. prepare timely, clear, well-written reports that include all the information required
by Appendix B to the CIA. 
  

	D.	IRO Independence and Objectivity. 

 The
IRO must perform the IRO Review in a professionally independent and objective fashion, as appropriate to the nature of the engagement, taking into account any other business relationships or engagements that may exist between the IRO and Allergan.

  

	E.	IRO Removal/Termination. 

1. Allergan Termination of IRO. If Allergan terminates its IRO during the course of the engagement, Allergan must submit a notice
explaining its reasons to OIG no later than 30 days after termination. Allergan must engage a new IRO in accordance with Paragraph A of this Appendix. 

2. OIG Removal of IRO. In the event OIG has reason to believe that the IRO does not possess the qualifications described in
Paragraph B, is not independent and/or objective as set forth in Paragraph D, or has failed to carry out its responsibilities as described in Paragraph C, OIG may, at its sole discretion, require Allergan to engage a new IRO in accordance with
Paragraph A of this Appendix. 
 Prior to requiring Allergan to engage a new IRO, OIG shall notify Allergan of its intent to do
so and provide a written explanation of why OIG believes such a step is necessary. To resolve any concerns raised by OIG, Allergan may request a meeting with OIG to discuss any aspect of the IRO’s qualifications, independence or performance of
its responsibilities and to present additional information regarding these matters. Allergan 
  

 2 

 
shall provide any additional information as may be requested by OIG under this Paragraph in an expedited manner. OIG will attempt in good faith to resolve any differences regarding the IRO with
Allergan prior to requiring Allergan to terminate the IRO. However, the final determination as to whether or not to require Allergan to engage a new IRO shall be made at the sole discretion of OIG. 

 

 3 

 Appendix B to CIA 

Promotional and Product Related Review 
  

	I.	Promotional and Product Related Review, General Description 

As specified more fully below, Allergan shall retain an Independent Review Organization (IRO) to perform reviews to assist Allergan in assessing and
evaluating its systems, processes, policies, procedures, and practices related to Allergan’s Promotional and Product Related Functions (IRO Review). The IRO Review shall consist of two components - a systems review (the “Promotional and
Product Related Systems Review” or “Systems Review”), and a transactions review (the “Promotional and Product Related Transactions Review” or “Transactions Review”) as described more fully below. Allergan may
engage, at its discretion, a single IRO to perform both components of the IRO Review provided that the entity has the necessary expertise and capabilities to perform both. 

If there are no material changes in Allergan’s systems, processes, policies, and procedures relating to Promotional and Product
Related Functions, the IRO shall perform the Systems Review for the first and fourth Reporting Periods. If Allergan materially changes its systems, processes, policies, and procedures relating to Promotional and Product Related Functions, the IRO
shall perform a Systems Review for the Reporting Period(s) in which such changes were made in addition to conducting the Review for the first and fourth Reporting Periods. The additional Systems Review(s) described in Section III.D.1.b of the CIA
shall consist of: 1) an identification of the material changes; 2) an assessment of whether other systems, processes, policies, and procedures previously reported did not materially change; and 3) a review of the systems, processes, policies, and
procedures that materially changed. The IRO shall conduct the Transactions Review for each Reporting Period of the CIA. 
  

	II.	IRO Systems Review 

  

	A.	Description of Reviewed Policies and Procedures 

The Promotional and Product Related Systems Review shall be a review of Allergan’s systems, processes, policies, and procedures (including the
controls on those systems, processes, policies, and procedures) relating to certain Promotional and Product Related Functions. Where practical, Allergan personnel may compile documentation, schedule and organize interviews, and undertake other
efforts to assist the IRO in performing the Systems Review. The IRO is not required to undertake a de novo review of the information gathered or activities undertaken by Allergan pursuant to the preceding sentence. 

 

 1 

 Specifically, the IRO shall review Allergan’s systems, processes, policies, and procedures associated
with the following (hereafter “Reviewed Policies and Procedures”): 

1)        Allergan’s systems, policies, processes, and procedures applicable to the manner
in which Allergan sales representatives handle and submit requests or inquiries to Medical Affairs relating to information about the uses of products (including non-FDA-approved (i.e., off-label) uses) and the dissemination of materials
relating to off-label uses of products. This review includes: 
  

	 	a)	the manner in which Allergan sales representatives handle and submit or generate requests for information about off-label uses of products to Medical Information
(including through the Information Request Management System (IRMS)); 

  

	 	b)	the manner in which Medical Information personnel handle and respond to requests for information about off-label uses (including tracking the requests and using the
materials provided in response to the request); 

  

	 	c)	the form and content of information and materials related to Products disseminated to physicians, pharmacists, or other health care professionals (collectively
“HCPs”) or health care institutions (HCIs) by Allergan; 

  

	 	d)	Allergan’s systems, processes, and procedures (including the Inquiries Database) used to track requests for information about off-label uses of products and
responses to those requests; 

  

	 	e)	the manner in which Allergan collects and supports information reported in any systems used to track and respond to requests for product information, including the
Inquiries Database; 

  

	 	f)	the processes and procedures by which Medical Information and Allergan’s Corporate Compliance Department or their designees monitor and identify situations in
which it appears that improper off-label promotion may have occurred; and 

  

	 	g)	Allergan’s processes and procedures for investigating, documenting, resolving, and taking appropriate disciplinary action for potential situations involving
improper promotion; 

 2)        Allergan’s systems, processes,
policies and procedures applicable to the manner and circumstances under which personnel from Medical Affairs (e.g., Regional Scientific Services, or RSS) interact with or participate in meetings or events with HCPs or HCIs (either alone or
with sales 
  

 2 

 
representatives) and the role of the medical personnel at such meetings or events, including the manner in which they handle responses to unsolicited requests about off-label indications of
Products. This includes any Medical Affairs Monitoring Plan designed to monitor the activities of the RSMs; 

3)        Allergan’s systems, policies, processes, and procedures relating to
Allergan’s internal review and approval of information and materials related to products disseminated to HCPs or HCIs by Allergan; 

4)        Allergan’s systems, processes, polices, and procedures relating to incentive
compensation for Relevant Covered Persons who are sales representatives, with regard to whether the systems, policies, processes, and procedures are designed to ensure that financial incentives do not inappropriately motivate such individuals to
engage in the improper promotion, sales, and marketing of Allergan’s products. This shall include a review of the bases upon which compensation is determined and the extent to which compensation is based on product performance. To the extent
that Allergan establishes different systems, processes, policies, or procedures relating to compensation for different products, the IRO shall review each type of compensation arrangement separately; 

5)        Allergan’s systems, processes, policies, and procedures relating to the
development and review of Call Plans (as defined in Section III.B.3.j of the CIA). This shall include a review of the bases upon which HCPs and HCIs belonging to specified medical specialties are included in, or excluded from, the Call Plans based
on, among other factors, expected utilization of products for FDA-approved uses or non-FDA-approved uses; 

6)        Allergan’s systems, processes, policies, and procedures relating to sample
distribution. This shall include a review of the bases upon, and circumstances under, which HCPs and HCIs belonging to specified medical specialties or types of clinical practice may receive samples from Allergan (including, separately, from
Allergan sales representatives and other Allergan personnel or components). It shall also include a review of whether samples of Products are distributed by Allergan through sales representatives or are distributed from a central location and the
rationale for the manner of distribution; 
 7)        Allergan’s systems
(including any centralized electronic system), processes, policies, and procedures relating to speaker programs, speaker training programs, and all events and expenses relating to such engagements or arrangements; 

 

 3 

 8)        Allergan’s systems, processes,
policies, and procedures relating to non-speaker related consultant or other fee-for-service arrangements entered into with HCPs or HCIs (including, but not limited to, presentations, consultant task force meetings, advisory boards, preceptorships,
mentorships (if any), and ad hoc advisory activities, and any other financial engagement or arrangement with an HCP or HCI) and all events and expenses relating to such engagements or arrangements; 

9)        Allergan’s systems, processes, policies and procedures relating to the submission
of information about any product to any compendia such as Drugdex or other published source of information used in connection with the determination of coverage by a Federal health care program for the Product (“Compendia”). This includes
any initial submission of information to any Compendia and the submission of any additional, updated, supplemental, or changed information, (e.g., any changes based on Allergan’s discovery of erroneous or scientifically unsound
information or data associated with the information in the Compendia.) The review shall also assess Allergan’s processes relating to its annual review of all arrangement, processing fees, or other payments or financial support (if any) provided
by the company to any Compendia; 
 10)        Allergan’s systems, processes,
policies, and procedures relating to investigator-initiated trials (IITs) including the decision to provide financial or other support for those studies; the manner in which support is provided for the IITs; and support for publication of the
information about those studies, including publication of information about the trial outcomes and results and the uses made of publications relating to those studies; 

11)        Allergan’s systems, processes, policies and procedures relating to authorship or
any articles or other publications about products or therapeutic areas or disease states that may be treated with products, including, but not limited to, the disclosure of any and all relationships between the author and Allergan, the
identification of all authors or contributors (including professional writer, if any) associated with a given publication, and the scope and breadth of research results made available to each author or contributor; and 

12) Allergan’s systems, processes, policies, and procedures relating to the provision of reimbursement support services, including
the controls around the provision of such services; the manner in which Allergan provides reimbursement support services; the frequency with which Allergan provides such services; and the determination about which HCPs or HCIs will be eligible to
receive such services. The review shall also assess 
  

 4 

 
Allergan’s processes relating to its annual review of reimbursement support services as referenced in Section III.B.3.f of the CIA. 

 

	B.	IRO Systems Review Report 

 The
IRO shall prepare a report based upon each Systems Review. For each of the Reviewed Policies and Procedures identified in Section II.A above, the report shall include the following items: 

1)        a description of the documentation (including policies) reviewed and any personnel
interviewed; 
 2)        a detailed description of Allergan’s systems, policies,
processes, and procedures relating to the items identified in Sections II.A.1-12 above, including a general description of Allergan’s control and accountability systems (e.g., documentation and approval requirements, and tracking
mechanisms) and written policies regarding the Reviewed Policies and Procedures; 

3)        a description of the manner in which the control and accountability systems and the
written policies relating to the items identified in Sections II.A.1-12 above are made known or disseminated within Allergan; 

4)        a detailed description of any system(s) used to track and respond to requests for
information about Allergan’s products (including the Inquiries Database); 

5)        a detailed description of Allergan’s incentive compensation system for Covered
Persons who are sales representatives, including a description of the bases upon which compensation is determined and the extent to which compensation is based on product performance. To the extent that Allergan may establish compensation
differently for individual products, the IRO shall report separately on each such type of compensation arrangement; 

6)        findings and supporting rationale regarding any weaknesses in Allergan’s systems,
processes, policies, and procedures relating to the Reviewed Policies and Procedures, if any; and 

7)        recommendations to improve any of the systems, policies, processes, or procedures
relating to the Reviewed Policies and Procedures, if any. 
  

 5 

	III.	IRO Transaction Review 

 As
described more fully below in Sections III.A-E, the Transactions Review shall include: (1) a review of a sample of Inquiries reflected in the Inquiries Database; (2) a review of Allergan’s Call Plans and Allergan’s Call Plan
review process; (3) a review of Sampling Events as defined below in Section III.C; (4) a review of records relating to a sample of the Payments that are reported by Allergan pursuant to Section III.M of the CIA; and (5) a review of up
to three additional items identified by the OIG in accordance with Section III.D.1.b of the CIA (hereafter “Additional Items”.) The IRO shall report on all aspects of its reviews in the Promotional and Product Related Transactions Review
Reports. 
  

	A.	Review of Inquiries and Inquiries Database 

  

	 	1)	Description of Inquiries Database 

As set forth in Section III.B.3.h of the CIA, Allergan shall establish a database (Inquiries Database) to track information relating to
all requests for information received by Allergan about its products (Inquiries). Allergan shall record in the Inquiries Database the following information for each Inquiry received: 1) date of Inquiry; 2) form of Inquiry (e.g., fax, phone,
medical information request form); 3) name of requesting HCP or HCI; 4) nature and topic of request including exact language of the Inquiry (if made in writing); 5) nature/form of the response from Allergan (including a record of any materials
provided in response to the request); and 6) the name of the Allergan representative who called upon or interacted with the HCP or HCI, if known. 
  

	 	2)	Internal Review of Inquiries Database 

On a semi-annual basis, the Chief Compliance Officer, or a designee, shall review the Inquiries Database and related information, as
appropriate, and shall generate a report summarizing the items of information outlined in Section III.A.1 above for each Inquiry received during the preceding two quarters (Inquiry Report). The Chief Compliance Officer shall review the Inquiry
Reports to assess whether the information contained in the report suggests that improper off-label promotion may have occurred in connection with any Inquiry(ies). If the Chief Compliance Officer, in consultation with other appropriate Allergan
personnel, suspects that improper off-label promotion may have occurred in connection with any Inquiry, the Chief Compliance Officer shall initiate a follow-up review of the Inquiry (Off-Label Review), make specific findings based on his/her
Off-Label Review, and take all appropriate responsive action (including 
  

 6 

 
disciplinary action of the Covered Person and reporting of the conduct, including disclosing Reportable Events pursuant to Section III.H of the CIA, if applicable). 

 

	 	3)	IRO Review of Inquiries Reflected in Inquiries Database 

The IRO shall select and review a random sample of 50 Inquiries from among the Inquiries reflected in the Inquiries Database for each
Reporting Period. Forty of the Inquiries reviewed by the IRO shall be Inquiries for which Allergan conducted an Off-Label Review, and the other 10 shall be Inquiries for which Allergan did not conduct an Off-Label Review. For each Inquiry reviewed,
the IRO shall determine: 
  

	 	a)	Whether each item of information listed above in Section III.A.1 is reflected in the Inquiries Database for each reviewed Inquiry; and 

 

	 	b)	For each Inquiry for which the Chief Compliance Officer conducted an Off-Label Review, the basis for suspecting that improper off-label promotion may have occurred; the
steps undertaken as part of the Off-Label Review; the findings of the Chief Compliance Officer as a result of the Off-Label Review; and any follow-up actions taken by Allergan based on the Off-Label Review findings. 

 

	B.	IRO Review of Allergan’s Call Plans and Call Plan Review Process 

The IRO shall conduct a review and assessment of Allergan’s review of its Call Plans as set forth in Section III.B.3.j of the CIA.
Allergan shall provide the IRO with: i) a list of products promoted by Allergan during the Reporting Period; ii) information about the FDA-approved uses for each Allergan product; and iii) the Call Plans for each product. Allergan shall also provide
the IRO with information about the reviews of Call Plans that Allergan conducted during the Reporting Period and any modifications to the Call Plans made as a result of Allergan’s reviews. 

For each Call Plan, the IRO shall select a sample of 50 of the HCPs and HCIs included on the Call Plan. For each Call Plan, the IRO shall
compare the sampled HCPs and HCIs against the criteria (e.g., medical specialty or practice area) used by Allergan in conducting its review and/or modification of the Call Plan in order to determine whether Allergan followed its
criteria and Policies and Procedures in reviewing and modifying the Call Plan. 
 The IRO shall note any instances in which it
appears that the sampled HCPs and HCIs on a particular Call Plan are inconsistent with Allergan’s criteria relating to the Call 

 

 7 

 
Plan and/or Allergan’s Policies and Procedures. The IRO shall also note any instances in which it appears that Allergan failed to follow its criteria or Policies and Procedures. 

 

	C.	IRO Review of the Distribution of Samples of Allergan Products 

The IRO shall conduct a review and assessment of the distribution of samples of Allergan products to HCPs and HCIs. Allergan shall
provide the IRO with: i) a list of products for which Allergan distributed samples during the Reporting Period; ii) information about the FDA-approved uses for each Allergan product; and iii) information about Allergan’s policies and procedures
relating to the distribution of samples of each type of product, including Allergan’s Call Plan showing which particular medical specialties or types of clinical practices are eligible to receive samples. Allergan shall also provide the IRO
with information about the reviews of Call Plans that Allergan conducted during the Reporting Period and any modifications to the plans made as a result of Allergan’s reviews. 

For each product for which Allergan distributed samples during the Reporting Period, the IRO shall randomly select a sample of 30
separate instances in which Allergan provided samples of the product to HCPs or HCIs. Each such instance shall be known as a “Sampling Event.” 

For each Sampling Event, the IRO shall review all documents and information relating to the distribution of the sample to the HCP or HCI.
The reviewed materials shall include materials about the following: 1) the quantity, dosage, and form of the Allergan product provided to the HCP or HCI; 2) the identity and type of medical specialty or clinical practice of the HCP or HCI; 3) which
individual Allergan sales representative or department (e.g., medical services) provided the sample to the HCP or HCI; 4) the manner and mechanism through which the sample was requested (e.g., sample request form, letter or call to Medical
Information department); and 5) the manner and mechanism through which the request was fulfilled (e.g., sales representative distribution or direct shipment.) 

For each Sampling Event, the IRO shall evaluate whether the sample was provided to an HCP or HCI whose medical specialty or clinical
practice is consistent with the uses of the product approved by the FDA and whether the sample was distributed by a Allergan representative in a manner consistent with Allergan’s sample distribution policy for the product(s) provided during the
Sampling Event. To the extent that a sample was provided to an HCP or HCI by an Allergan representative other than a sales representative, the IRO shall contact the HCP or HCI by letter. The letter shall request that the HCP or HCI: 1) verify that
he/she/it received the quantity and type of samples identified by the IRO as the Sampling Event; 2) verify that he/she/it requested the samples provided during the Sampling Event; 3) explain or confirm its type of medical specialty or clinical
practice; and 4) identify the basis for requesting the sample (e.g., 
  

 8 

 
conversations with a Allergan sales representative, conversation with a representative of Allergan’s Medical Information department, independent research or knowledge of the HCP or HCI,
etc.) 
 For each Sampling Event, the IRO shall compare the medical specialty and type of clinical practice of the HCPs
and HCIs that received the sample with uses of the product approved by the FDA. The IRO shall note any instances in which it appears that the medical specialty or clinical practice of the HCPs or HCIs that received a sample during a Sampling Event
were not consistent with the uses of the product approved by the FDA. For each such situation, the IRO shall note the process followed by Allergan in determining that it was appropriate to provide a sample to such HCP or HCI and the basis for such
determination. The IRO shall also note any instances in which it appears that Allergan failed to follow its Call Plan for the product(s) provided during the Sampling Event. 

 

	D.	IRO Review of Physician Payment Listings 

  

	 	1.	Information Contained in Physician Payment Listings 

As set forth in Section III.M of the CIA, in phases, Allergan shall post quarterly and annual listings of physicians and Related Entities
who received Payments, as defined in the CIA, directly or indirectly from Allergan. For purposes of the IRO review as set forth in this Section III.D, each annual listing shall be referred to as the “Physician Payment Listing” or
“Listing.” For each physician and Related Entity, each Physician Payment Listing shall include the following information: i) full name; ii) name of Related Entity (if applicable); iii) city and state of the physician’s practice or the
Related Entity; and iv) the aggregate value of the Payment(s) in the preceding year. 
 For purposes of this IRO review, the
term “Control Documents” shall include all documents or electronic records associated with each Payment reflected in the Physician Payments Listing for the sampled physician and/or Related Entity. For example, the term “Control
Documents” includes, but is not limited to, documents relating to the nature, purpose, and amount of all Payments reflected in the Listing; contracts relating to the Payment(s) reflected in the Listing; documents relating to the occurrence of
Payment(s) reflected in the Listing; documents reflecting any work product generated in connection with the Payment(s); documents submitted by sales representatives or headquarters personnel to request approval for the Payment(s); and business
rationale or justification forms relating to the Payment(s). 
  

	 	2.	Selection of Sample for Review 

For each Reporting Period, the OIG shall have the discretion to identify up to 50 physicians or Related Entities from the applicable
Physician Payment Listing that will be 
  

 9 

 
subject to the IRO review described below. If the OIG elects to exercise this discretion, it shall notify the IRO of the physicians and/or Related Entities subject to the IRO review. If the OIG
elects not to exercise its discretion as described above, the IRO shall randomly select 50 physicians and/or Related Entities to be included in the review. For each selected physician and/or Related Entity, the IRO shall review the entry in the
Physician Payment Listing and the Control Documents relating to Payments reflected in Listing identified by the IRO as necessary and sufficient to validate the Payment information in the Listing. 

 

	 	3.	IRO Review of Control Documents for Selected Physicians and/or Related Entities 

For each physician and/or Related Entity selected as part of the sample, the IRO shall review the Control Documents identified by the IRO
as necessary and sufficient to validate each Payment reflected in the Listing to evaluate the following: 
  

	 	a)	Whether Control Documents are available relating to each Payment reflected in the Listing for the sampled physician and/or Related Entity; 

 

	 	b)	Whether the Control Documents were completed and archived in accordance with the requirements set forth in Allergan’s policies; 

 

	 	c)	Whether the aggregate value of the Payment(s) as reflected in the Listing for the sampled Physician is consistent with the value of the Payment(s) reflected in the
Control Documents; and 

  

	 	d)	Whether the Control Documents reflect that Allergan’s policies were followed in connection with Payment(s) reflected in the Listing (e.g., all required
written approvals for the activity were obtained in accordance with Allergan’s policies.) 

  

	 	4.	Identification of Material Errors and Additional Review 

A Material Error is defined as any of the following: 
  

	 	a)	A situation in which all required Control Documents relating to Payments reflected in the Listing for the sampled physician and/or Related Entity do not exist and:

  

	 	 i.	no corrective action was initiated prior to the selection of the sampled physicians and/or Related Entities; or 

 

	 	ii.	 the IRO cannot confirm that Allergan otherwise followed its policies and procedures relating to the entry in the

  

 10 

	 	 
Listing for the sampled physician or Related Entity, including its policies and procedures relating to any Payment(s) reflected in the Listing; or 

 

	 	b)	Information or data is omitted from key fields in the Control Documents that prevents the IRO from assessing compliance with Allergan’s policies and procedures,
and the IRO cannot obtain this information or data from reviewing other Control Documents. 

 If a Control
Document does not exist, but Allergan has initiated corrective action prior to the selection of the sampled physicians and/or Related Entities, or if a Control Document does not exist but the IRO can determine that Allergan otherwise followed its
policies and procedures with regard to each entry in the Listing for a sampled physician or Related Entity, the IRO shall consider such a situation to be an exception (rather than a Material Error) and the IRO shall report the situation as such.
Similarly, the IRO shall note as exceptions any Control Documents for which non-material information or data is omitted. 
 If
the IRO identifies any Material Errors, the IRO shall conduct such Additional Review of the underlying Payment associated with the erroneous Control Documents as may be necessary to determine the root cause of the Material Errors. For example, the
IRO may need to review additional documentation and/or conduct interviews with appropriate personnel to identify the root cause of the Material Error(s) discovered. 
  

	E.	IRO Review of Additional Items 

As set forth in Section III.D.1.b of the CIA, for each Reporting Period, the OIG at its discretion may identify up to three additional
items for the IRO to review (hereafter “Additional Items”.) No later than 150 days prior to the end of the applicable Reporting Period, the OIG shall notify Allergan of the nature and scope of the IRO review to be conducted for each of the
Additional Items. Prior to undertaking the review of the Additional Items, the IRO and/or Allergan shall submit an audit work plan to the OIG for approval and the IRO shall conduct the review of the Additional Items based on a work plan approved by
the OIG. The IRO shall include information about its review of each Additional Item in the Transactions Review Report (including a description of the review conducted for each Additional Item; the IRO’s findings based on its review for each
Additional Item; and the IRO’s recommendations for any changes in Allergan’s systems, processes, policies, and procedures based on its review of each Additional Item.) 

Allergan may propose to the OIG that its internal audit(s) and/or reviews conducted as part of the Field Force Monitoring Program (FFMP)
described in Section III.J of the CIA or the Non-Promotional Monitoring Program described in Section III.K of the CIA be substituted for one or more of the Additional Items that would otherwise be

  

 11 

 
reviewed by the IRO for the applicable Reporting Period. The OIG retains sole discretion over whether, and in what manner, to allow Allergan’s internal audit work and monitoring activities
to be substituted for a portion of the Additional Items review conducted by the IRO. 
 In making its decision, the OIG agrees
to consider, among other factors, the nature and scope of Allergan’s planned monitoring activities and internal audit work, the results of the Transactions Review(s) during prior Reporting Period(s), and Allergan’s demonstrated audit
capabilities to perform the proposed audit work internally. If the OIG denies Allergan’s request to permit its monitoring activities or internal audit work to be substituted for a portion of the IRO’s review of Additional Items in a given
Reporting Period, Allergan shall engage the IRO to perform the Review as outlined in this Section III. 
 If the OIG agrees to
permit certain of Allergan’s monitoring activities or internal audit work for a given Reporting Period to be substituted for a portion of Additional Items review, such internal work would be subject to verification by the IRO (Verification
Review). In such an instance, the OIG would provide additional details about the scope of the Verification Review to be conducted by the IRO. However, for purposes of any Verification Review, the IRO shall review at least 20% of the sampling units
reviewed by Allergan in its internal audits. 
  

	F.	Promotional and Product Related Transactions Review Report 

For each Reporting Period, the IRO shall prepare a report based on its Promotional and Product Related Transactions Review. The report
shall include the following: 
  

	 	1)	General Elements to Be Included in Report 

  

	 	a)	Review Objectives: A clear statement of the objectives intended to be achieved by each part of the review; 

 

	 	b)	Review Protocol: A detailed narrative description of the procedures performed and a description of the sampling unit and universe utilized in performing the procedures
for each sample reviewed; and 

  

	 	c)	Sources of Data: A full description of documentation and other information, if applicable, relied upon by the IRO in performing the Promotional and Product Related
Transactions Review. 

  

	 	2)	Results to be Included in Report 

  

 12 

 The following results shall be included in each Promotional and Product Related
Transactions Review Report: 
 (Relating to the Review of Inquiries) 

 

	 	a)	in connection with the review of Inquiries, a description of each type of sample unit reviewed, including the number of each type of sample units reviewed (e.g.,
the number of Inquiries) and an identification of the types of documents and information reviewed for the Inquiries; 

  

	 	b)	for each Inquiry sample unit, the IRO shall summarize the information about the Inquiry contained in the Inquiries Database; 

 

	 	c)	for each Inquiry sample unit, findings and supporting rationale as to whether: (i) each item of information listed in Section III.A.1 is reflected in the Inquiries
Database; and (ii) for each Inquiry for which an Off-Label Review was conducted, the basis for suspecting that improper off-label promotion may have occurred; the steps undertaken as part of the Off-Label Review; the findings of the Chief
Compliance Officer as a result of the Off-Label Review; and any follow-up actions taken by Allergan as a result of the Chief Compliance Officer’s findings; 

 

	 	d)	the findings and supporting rationale regarding any weaknesses in Allergan’s systems, processes, policies, procedures, and practices relating to the Inquiries, and
the Inquiries Database, if any; 

  

	 	e)	recommendations for improvement in Allergan’s systems, processes, policies, procedures, and practices relating to the Inquiries and the Inquiries Database, if any;

 (Relating to the Call Plan Reviews) 

 

	 	f)	a list of the products promoted by Allergan during the Reporting Period and a summary of the FDA-approved uses for such products; 

 

	 	g)	 for such Allergan products: i) a description of the criteria used by Allergan in developing or reviewing the Call Plans and for including or excluding
specified types of HCPs or HCIs from the Call Plans; ii) a description of the review conducted by Allergan of the Call Plans and an indication of whether Allergan reviewed the Call Plans as required by Section III.B.3.j of the CIA; iii) a
description of all 

  

 13 

	 	 
instances for each Call Plan in which it appears that the HCPs and HCIs included on the Call Plan are inconsistent with Allergan’s criteria relating to the Call Plan and/or Allergan’s
Policies and Procedures; and iv) a description of all instances in which it appears that Allergan failed to follow its criteria or Policies and Procedures relating to Call Plans or the review of the Call Plans; 

 

	 	h)	the findings and supporting rationale regarding any weaknesses in Allergan’s systems, processes, policies, procedures, and practices relating to Allergan’s
Call Plans or the review of the Call Plans, if any; 

  

	 	i)	recommendations, if any, for changes in Allergan’s systems, processes, policies, procedures, and practices that would correct or address any weaknesses or
deficiencies uncovered during the Transactions Review with respect to Call Plans or the review of the Call Plans; 

(Relating to the Sampling Event Reviews) 
  

	 	j)	for each Allergan product distributed during the Reporting Period: i) a description of the Call Plan (including whether sales representatives may provide samples of the
product and, if so, to HCPs or HCIs of which medical specialty or type of clinical practice a sales representative may provide samples); ii) a detailed description of any instances in which it appears that the medical specialty or clinical practice
of the HCPs or HCIs that received a sample during a Sampling Event were not consistent with the uses of the product approved by the FDA. This description shall include a description of the process followed by Allergan in determining that it was
appropriate to provide a sample to such HCP or HCI and the basis for such determination; and iii) a detailed description of any instances in which it appears that Allergan failed to follow its Call Plan for the product(s) provided during the
Sampling Event; 

  

	 	k)	the findings and supporting rationale regarding any weaknesses in Allergan’s systems, processes, policies, procedures, and practices relating to Allergan’s
distribution of samples of Allergan products, if any; 

  

	 	l)	 recommendations, if any, for changes in Allergan’s systems, processes, policies, procedures, and practices that would correct or

  

 14 

	 	 
address any weaknesses or deficiencies uncovered during the Transactions Review with respect to the distribution of samples; 

(Relating to the Physician Payment Listing Reviews) 
  

	 	m)	a description of the entries in the Physician Payment Listing for each physician or Related Entity sampled and a description of Control Documents reviewed in connection
with each selected physician or Related Entity; 

  

	 	n)	for each sampled physician or Related Entity, findings and supporting rationale as to whether: (i) all required Control Documents exist; (ii) each Control
Document was completed in accordance with all of the requirements set forth in the applicable Allergan policy; (iii) the aggregate value of the Payment(s) as reflected in the Listing for the sampled physician or entity is consistent with the
value of the Payment(s) reflected in the Control Documents; (iv) each Control Document reflects that Allergan’s policies were followed in connection with the underlying activity reflected in the document (e.g., all required
approvals were obtained); and (v) any corrective action or disciplinary action was undertaken in those instances in which Allergan policies were not followed; 

 

	 	o)	for each sampled physician or Related Entity unit reviewed, an identification and description of all exceptions discovered. The report shall also describe those
instances in which corrective action was initiated prior to the selection of the sampled physicians or Related Entities, including a description of the circumstances requiring corrective action and the nature of the corrective action;

  

	 	p)	if any Material Errors are discovered in any sample unit reviewed, a description of the error, the Additional Review procedures performed and a statement of findings as
to the root cause(s) of the Material Error; 

 (Relating to the Review of Additional Items) 

 

	 	q)	for each Additional Item reviewed, a description of the review conducted; 

  

	 	r)	for each Additional Item reviewed, the IRO’s findings based on its review; 

 

 15 

	 	s)	for each Additional Item reviewed, the findings and supporting rationale regarding any weaknesses in Allergan’s systems, processes, policies, procedures, and
practices relating to the Additional Item, if any; and 

  

	 	t)	for each Additional Item reviewed, recommendations, if any, for changes in Allergan’s systems, processes, policies, and procedures that would correct or address
any weaknesses or deficiencies uncovered during the review. 

  

 16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00178-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00178-of-00352.parquet"}]]